RESULT_COUNT: 401,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
AERI,AERI:US,BBG001KJ7WJ5,Rhopressa Could Be Major Growth Driver for Aerie Pharmaceuticals,2017-10-19 19:05:49 +0000,http://finance.yahoo.com/r/ec0fcb40-6a3c-305f-920f-604dd9bbfb5d/rhopressa-may-prove-major-growth-driver-aerie-pharmaceuticals-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Aerie Pharmaceuticals (AERI) is currently preparing for the launch of its investigational glaucoma drug, Rhopressa."
AERI,AERI:US,BBG001KJ7WJ5,AERI Expects to Benefit from Demand in Glaucoma Segment,2017-10-19 17:36:06 +0000,http://finance.yahoo.com/r/852cb4b9-3d31-3261-ae00-40fd7250eb9f/aerie-pharmaceuticals-expects-benefit-significant-demand-glaucoma-segment-2018?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Aerie Pharmaceuticals (AERI) reported GAAP net loss worth $28.4 million, which is higher than the $23.2 million loss reported in 2Q16."
AERI,AERI:US,BBG001KJ7WJ5,What Analysts Recommend for Aerie Pharmaceuticals in October 2017,2017-10-19 15:53:52 +0000,http://finance.yahoo.com/r/5db46e5b-ae69-3157-8df0-4a7b325acc29/analysts-recommendations-aerie-pharmaceuticals-peers-october-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On October 13, 2017, the US Food and Drug Administration’s Dermatologic and Ophthalmic Drugs Advisory Committee recommended the approval of Aerie Pharmaceuticals’ (AERI) investigational glaucoma drug."
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Up on FDA Review Committee Result for Rhopressa,2017-10-17 21:59:09 +0000,https://finance.yahoo.com/news/aerie-aeri-fda-review-committee-215909645.html?.tsrc=rss,"Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa."
AERI,AERI:US,BBG001KJ7WJ5,This Biotech Yo-Yos After FDA Panel Recommends Glaucoma Drug,2017-10-13 22:15:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MOSeG2fqkP0/this-biotech-yo-yos-after-fda-panel-recommends-glaucoma-drug-cm859683,A split Food and Drug Administration committee voted Friday to recommend approval for Aerie Pharmaceuticals AERI glaucoma drug Rhopressa 160 sending the company s stock yo yoing after it was briefly halted in early trades ibd display video id 2359787 width 50 float
AERI,AERI:US,BBG001KJ7WJ5,"With nod from panel, Aerie inches toward FDA approval",2017-10-13 21:20:10 +0000,http://finance.yahoo.com/r/53aae374-62ec-3b4d-8fc1-4271e468a295/with-nod-from-panel-aerie-inches-toward-fda.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Aerie Pharmaceuticals (AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval.  “We are delighted with the outcome of the FDA’s Advisory Committee, and we now have our sights set on the February 28th PDUFA date,” stated Vicente Anido Jr., chairman and CEO of Aerie."
AERI,AERI:US,BBG001KJ7WJ5,U.S. FDA panel backs Aerie's glaucoma drug Rhopressa,2017-10-13 17:32:46 +0000,https://finance.yahoo.com/news/u-fda-panel-backs-aeries-173246109.html?.tsrc=rss,"Aerie Pharmaceuticals Inc's  experimental glaucoma treatment should be approved, an advisory  committee to the U.S. Food and Drug Administration said on  Friday, after it found the benefits outweigh the risks.  The panel voted 9-1 in favor of the drug, Rhopressa, the  first in a new class of treatments for glaucoma, an eye  condition that is the second-leading cause of blindness in the  world.  The FDA is not obliged to follow the recommendations of its  advisory panels but typically does."
AERI,AERI:US,BBG001KJ7WJ5,Jacobs' South African JV Business Wins New Deal from Sasol,2017-10-13 16:17:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a99Rr1DUWyI/jacobs-south-african-jv-business-wins-new-deal-from-sasol-cm859469,Jacobs Engineering Group Inc JEC further strengthened its long term relationship with Sasol Group Technology on the back of a new two year long project management service contract win Over the last six months Jacobs shares yielded a return of 10 5 outperforming 5 2 growth recorded
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals stock halted for FDA committee review of glaucoma treatment,2017-10-13 11:33:09 +0000,http://finance.yahoo.com/r/dc1a0610-f603-3a48-927a-fee9dce8a4f8/Story.aspx?guid=D9F229A8-B35E-44EE-99C8-5E6031DA290B&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Aerie Pharmaceuticals Inc. were halted for trading Friday, as the U.S. Food and Drugs Administration reviews a new drug application for a treatment for glaucoma and ocular hypertension. The FDA's ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Stock Trading Halted Today,2017-10-13 11:05:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-stock-trading-halted-110500482.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that NASDAQ has halted trading of the Company’s common stock."
AERI,AERI:US,BBG001KJ7WJ5,Jacobs (JEC) Signs Technology Licensor Deal With Paqell,2017-10-12 17:14:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KCwzziHFkw4/jacobs-jec-signs-technology-licensor-deal-with-paqell-cm858942,J acobs Engineering Group Inc JEC recently inked a sulfur recovery technology licensor covenant with Paqell Per the deal Pagell would be able to use Jacob s state of the art THIOPAQ Oil and Gas O amp G technology in all of its gas treating facilities and refineries across the world
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Scores Relative Strength Rating Upgrade,2017-10-12 15:16:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FC964KSpffo/aerie-pharmaceuticals-scores-relative-strength-rating-upgrade-cm858864,On Thursday Aerie Pharmaceuticals AERI hit an important technical milestone with its Relative Strength RS Rating jumping into the 90 plus percentile with an improvement to 93 a rise from 82 the day before ibd display video id 449423 width 50 float
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals (AERI) Surges: Stock Moves 16.2% Higher,2017-10-12 12:30:12 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-aeri-surges-stock-123012078.html?.tsrc=rss,"Aerie Pharmaceuticals (AERI) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes."
AERI,AERI:US,BBG001KJ7WJ5,"AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back",2017-10-11 21:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/udFdET8qXwM/aeri-faces-dday-pti-to-report-data-in-q4-mack-makes-peace-mnkd-pulls-back-20171011-01296,"AERI Faces D-Day, PTI To Report Data In Q4, MACK Makes Peace, MNKD Pulls Back"
AERI,AERI:US,BBG001KJ7WJ5,A Drug Sent This Biotech To A Fresh High — But There's A Caveat,2017-10-11 21:13:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yGGDsHqHqpI/a-drug-sent-this-biotech-to-a-fresh-high-but-theres-a-caveat-cm858184,Aerie Pharmaceuticals AERI jumped to a fresh high Wednesday after the Food and Drug Administration agreed the company s drug Rhopressa is effective in lowering eye pressure at the root of glaucoma ibd display video id 2349756 width 50 float left autostart true But there
AERI,AERI:US,BBG001KJ7WJ5,"Health Care Sector Update for 10/11/2017: AERI,AKTX,ATEC",2017-10-11 20:30:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2IDtL-vc7Vc/health-care-sector-update-for-10112017-aeriaktxatec-cm858445,Top Health Care StocksTop Health Care Stocks JNJ 2 12 JNJ 2 12 PFE 0 12 PFE 0 12 ABT 1 89 ABT 1 89 MRK 1 08 MRK 1 08 AMGN 0 86 AMGN 0 86 Health care stocks attracted investor attention in defensive trade with the NYSE Health Care Index Wednesday advancing nearly 0 4 while shares
AERI,AERI:US,BBG001KJ7WJ5,A Drug Sent This Biotech To A Fresh High — But There&apos;s A Caveat,2017-10-11 20:29:27 +0000,http://finance.yahoo.com/r/726a32f8-770e-396e-9fd2-8ac7e2d3e178/a-glaucoma-drug-just-sent-this-biotech-to-a-fresh-high?src=A00220&yptr=yahoo&.tsrc=rss,"Aerie jumped to a fresh high after the FDA agreed the company&apos;s drug, Rhopressa, lowers eye pressure in glaucoma."
AERI,AERI:US,BBG001KJ7WJ5,Wednesday's ETF with Unusual Volume: IWV,2017-10-11 18:11:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y0kyj-tCVP8/wednesdays-etf-with-unusual-volume-iwv-cm858332,The iShares Russell 3000 ETF IWV is seeing unusually high volume in afternoon trading Wednesday with over 789 000 shares traded versus three month average volume of about 148 000 Shares of IWV were up about 0 1 on the day Components of that ETF with the highest volume on
AERI,AERI:US,BBG001KJ7WJ5,"Notable Wednesday Option Activity: AERI, STZ, DNKN",2017-10-11 17:12:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aFw7eNFiHwc/notable-wednesday-option-activity-aeri-stz-dnkn-cm858295,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Aerie Pharmaceuticals Inc Symbol AERI where a total of 4 042 contracts have traded so far representing approximately 404 200 underlying shares That amounts to about 46 6 of AERI
AERI,AERI:US,BBG001KJ7WJ5,FDA review says Aerie glaucoma drug effectively lowers eye pressure; shares jump,2017-10-11 13:54:33 +0000,https://finance.yahoo.com/news/aeries-glaucoma-drug-effectively-lowers-133319842.html?.tsrc=rss,"Aerie Pharmaceuticals Inc's  experimental glaucoma treatment Rhopressa is effective in  lowering eye pressure a preliminary review by the U.S. Food and  Drug Administration, has concluded, sending Aerie's shares up as  much as 19 percent.  The review, posted on Wednesday on the FDA's website, comes  two days ahead of a meeting of outside experts who will advise  the agency on whether the treatment should be approved.  Glaucoma, a condition caused by damage to the optic nerve,  is the second-leading cause of blindness in the world."
AERI,AERI:US,BBG001KJ7WJ5,Aerie's glaucoma drug effectively lowers eye pressure-FDA review,2017-10-11 12:56:43 +0000,https://finance.yahoo.com/news/aeries-glaucoma-drug-effectively-lowers-125643715.html?.tsrc=rss,"Aerie Pharmaceuticals Inc's  experimental glaucoma treatment Rhopressa is effective in  lowering eye pressure, a preliminary review by the U.S. Food and  Drug Administration concluded.  The review, posted on Wednesday on the FDA's website, comes  two days ahead of a meeting of outside experts who will advise  the agency on whether the treatment should be approved.  Glaucoma, a condition caused by damage to the optic nerve,  is the second-leading cause of blindness in the world."
AERI,AERI:US,BBG001KJ7WJ5,Featured Company News - Aerie Expands Research Team; Set to Focus on Drug Delivery Asset Acquired from Envisia,2017-10-11 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-aerie-expands-114000212.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) (""Aerie""), ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Inc. (AERI) Has Jumped To A New High On FDA News,2017-10-11 09:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2ee1yfsJZNI/aerie-pharmaceuticals-inc-aeri-has-jumped-to-a-new-high-on-fda-news-20171011-00653,Aerie Pharmaceuticals Inc. (AERI) Has Jumped To A New High On FDA News
AERI,AERI:US,BBG001KJ7WJ5,Stocks Showing Rising Market Leadership: Aerie Pharmaceuticals Earns 82 RS Rating,2017-10-11 07:00:00 +0000,http://finance.yahoo.com/r/aa9a8b76-bcc2-3c7a-b7fd-5991a0680f1a/stocks-showing-rising-market-leadership-aerie-pharmaceuticals-earns-82-rs-rating?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Aerie Pharmaceuticals shows improving technical performance.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team,2017-10-09 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-members-103000054.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of 11 employees to its Research and Development team located in Durham, NC."
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-10-06 12:02:44 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120244070.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,Company Spotlight: Aerie Pharmaceuticals,2017-10-06 04:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cNxjQG6aH3M/company-spotlight-aerie-pharmaceuticals-20171006-00104,Company Spotlight: Aerie Pharmaceuticals
AERI,AERI:US,BBG001KJ7WJ5,Jacobs (JEC) Wins New Transportation Contracts from NTA,2017-10-05 17:48:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0w4w34HbgQY/jacobs-jec-wins-new-transportation-contracts-from-nta-cm855885,Jacobs Engineering Group Inc JEC recently secured a number of contracts from the National Transport Authority NTA of Ireland to support the latter s ongoing sustainable transportation projects Over the last six months shares of this Zacks Rank 3 Hold company have yielded a return
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Further Advance Its Retinal Disease Program,2017-10-05 10:00:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-drug-delivery-100000216.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has acquired from Envisia Therapeutics Inc."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold,2017-10-05 07:00:00 +0000,http://finance.yahoo.com/r/50e3c37e-1cbf-39f4-9fe1-dc67bcad59af/aerie-pharmaceuticals-earns-relative-strength-rating-upgrade-hits-key-threshold?src=A00220&yptr=yahoo&.tsrc=rss,Aerie Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.
AERI,AERI:US,BBG001KJ7WJ5,"Jacobs (JEC) Poised to Grow on Divestitures, Contract Wins",2017-10-03 20:54:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jJ3pzAf5MTA/jacobs-jec-poised-to-grow-on-divestitures-contract-wins-cm854819,Jacobs Engineering Group Inc JEC recently divested 40 interest in Neste Jacobs Oy and also secured a contract extension from the United States Air Force Communication Navigation Surveillance Air Traffic Management CNS ATM Shares of this Zacks Rank 3 Hold company were up nearly 1 1
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Sees IBD RS Rating Climb To 73,2017-10-03 07:00:00 +0000,http://finance.yahoo.com/r/6b2273de-ca0a-3566-9f08-4b0ba6705706/aerie-pharmaceuticals-sees-ibd-rs-rating-climb-to-73?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Aerie Pharmaceuticals shows improving technical performance. Will it continue?
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Ann Keevans as Director of Human Resources - Europe,2017-10-02 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-ann-103000839.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Ann Keevans as Director of Human Resources - Europe, reporting to Kathleen McGinley, Vice President of Human Resources and Corporate Services."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team,2017-09-29 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-members-103000771.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of David Biddell as Regional Sales Director for the Southeast Region, reporting to Gary Menichini, Aerie’s Vice President of Sales, and Shaun Gentry and ..."
AERI,AERI:US,BBG001KJ7WJ5,Biotech Stocks Facing FDA Decision In October,2017-09-29 07:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nmihicMyCXk/biotech-stocks-facing-fda-decision-in-october-20170929-00332,Biotech Stocks Facing FDA Decision In October
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-28 12:03:47 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120223589.html?.tsrc=rss,Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan.  The net inflows of $2.49 billion over the last one-month into ETFs that hold AERI are not among the highest of the last year and have been slowing.
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-27 12:03:42 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120342816.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-26 12:02:25 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120225879.html?.tsrc=rss,Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan.  The net inflows of $2.08 billion over the last one-month into ETFs that hold AERI are not among the highest of the last year and have been slowing.
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons",2017-09-25 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-sheila-103000024.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons, reporting to Welyn Bui, PharmD, Aerie’s National Director of Medical ..."
AERI,AERI:US,BBG001KJ7WJ5,First Week of AERI May 2018 Options Trading,2017-09-21 18:38:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hN7K9vS9hws/first-week-of-aeri-may-2018-options-trading-cm849180,Investors in Aerie Pharmaceuticals Inc Symbol AERI saw new options begin trading this week for the May 2018 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 239 days until expiration the newly trading
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-21 12:02:34 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120234130.html?.tsrc=rss,Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan.  This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on September 19.
AERI,AERI:US,BBG001KJ7WJ5,Corporate News Blog - Aerie Pharma Appoints Tori Arens as VP of Drug Product Manufacturing and Eric Carlson as VP of R&D,2017-09-21 11:20:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-aerie-pharma-112000718.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / September 21, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aerie Pharmaceuticals , Inc. (NASDAQ: AERI ) (""Aerie""), ..."
AERI,AERI:US,BBG001KJ7WJ5,"FDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ",2017-09-21 01:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8sL35mMdux0/fda-nod-for-abmd-aeri-faces-fda-panel-in-oct-ipci-put-on-notice-pfe-sues-jnj-20170921-00016,"FDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Tumbles Ahead Of FDA Panel Review Of Glaucoma Drug,2017-09-20 20:14:47 +0000,http://finance.yahoo.com/r/66b2abf0-2e4b-3d5b-9cf0-2023b97c7d5a/aerie-tumbles-ahead-of-fda-panel-review-of-glaucoma-drug?src=A00220&yptr=yahoo&.tsrc=rss,"Aerie dipped to a three-week low on volatility ahead of a FDA committee review of its glaucoma drug, Rhopressa."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa™ (netarsudil ophthalmic solution) 0.02%,2017-09-20 20:01:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-fda-advisory-200100146.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S."
AERI,AERI:US,BBG001KJ7WJ5,Jacobs (JEC) Awarded EPCM Contract by Aerie Pharmaceuticals,2017-09-20 16:40:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bv91QOAd52U/jacobs-jec-awarded-epcm-contract-by-aerie-pharmaceuticals-cm848439,Jacobs Engineering Group Inc JEC recently secured an engineering procurement and construction management services EPCM contract from Aerie Pharmaceuticals Inc AERI for an undisclosed amount Over the last month shares of Jacobs yielded a return of 14 7 outperforming 11 6
AERI,AERI:US,BBG001KJ7WJ5,Jacobs (JEC) Awarded EPCM Contract by Aerie Pharmaceuticals,2017-09-20 14:43:02 +0000,https://finance.yahoo.com/news/jacobs-jec-awarded-epcm-contract-144302717.html?.tsrc=rss,"Jacobs Engineering Group (JEC) to offer engineering, procurement and construction management services in the first pharmaceutical manufacturing plant of Aerie Pharmaceuticals Inc. (AERI)."
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-20 12:02:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120236494.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development",2017-09-19 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-tori-103000599.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other diseases of the eye, today announced the appointment of Tori Arens as Vice President of Drug Product Manufacturing, reporting to Kenneth Ruettimann, Ph.D., Aerie’s Vice President of Manufacturing...."
AERI,AERI:US,BBG001KJ7WJ5,Are Options Traders Betting on a Big Move in Aerie (AERI) Stock?,2017-09-13 14:40:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6xwn2LGXvP4/are-options-traders-betting-on-a-big-move-in-aerie-aeri-stock-cm845008,Investors in Aerie Pharmaceuticals Inc AERI need to pay close attention to the stock based on moves in the options market lately That is because the Sep 15 th 2017 160 40Put had some of the highest implied volatility of all equity options today What is Implied
AERI,AERI:US,BBG001KJ7WJ5,Are Options Traders Betting on a Big Move in Aerie (AERI) Stock?,2017-09-13 12:53:12 +0000,https://finance.yahoo.com/news/options-traders-betting-big-move-125312694.html?.tsrc=rss,"Investors in Aerie Pharmaceuticals, Inc. (AERI) need to pay close attention to the stock based on moves in the options market lately."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) to Ring The Nasdaq Stock Market Closing Bell",2017-09-11 14:00:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-inc-nasdaq-aeri-140000399.html?.tsrc=rss,"What: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma ..."
AERI,AERI:US,BBG001KJ7WJ5,Why Is Aerie (AERI) Up 10% Since the Last Earnings Report?,2017-09-11 11:49:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_tIcvVr5rAM/why-is-aerie-aeri-up-10-since-the-last-earnings-report-cm843478,It has been more than a month since the last earnings report for Aerie Pharmaceuticals Inc AERI Shares have added about 10 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a
AERI,AERI:US,BBG001KJ7WJ5,Why Is Aerie (AERI) Up 10% Since the Last Earnings Report?,2017-09-11 09:15:09 +0000,https://finance.yahoo.com/news/why-aerie-aeri-10-since-091509878.html?.tsrc=rss,Aerie (AERI) reported earnings more than a month ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan,2017-09-07 15:58:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iRa9UBr0-KY/aerie-initiates-phase-iii-study-for-ophthalmic-drug-roclatan-cm842311,Aerie Pharmaceuticals Inc AERI announced the initiation of phase III study Mercury 3 in Europe for its pipeline candidate Roclatan 0 02 0 005 Roclatan is a once daily quadruple action fixed dose combination of Rhopressa and Pfizer s PFE Xalatan iis being evaluated to lower
AERI,AERI:US,BBG001KJ7WJ5,Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan,2017-09-07 13:41:01 +0000,https://finance.yahoo.com/news/aerie-initiates-phase-iii-study-134101098.html?.tsrc=rss,"Aerie Pharmaceuticals, (AERI) announced that it has commenced phase III study -Mercury 3 in Europe for its pipeline candidate Roclatan 0.02%/0.005%."
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-07 12:03:38 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120338127.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at Two Investor Conferences in September,2017-09-06 11:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-present-two-investor-113000428.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in September."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,2017-09-06 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-initiates-mercury-3-103000425.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the commencement of patient dosing in Mercury 3, the Company’s European Phase 3 clinical trial of RoclatanTM 0.02%/0.005%, a novel once-daily eye drop ..."
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-09-01 12:02:34 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120234804.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-31 12:07:13 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120229650.html?.tsrc=rss,"Short interest is moderately high for AERI with between 10 and 15% of shares outstanding currently on loan.  This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on August 29.  Over the last month, growth of ETFs holding AERI is favorable, with net inflows of $3.94 billion."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Deanne Melloy as Vice President of Marketing and Norbert Lowe as Regional Sales Director,2017-08-28 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-deanne-103000533.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Deanne Melloy as Vice President of Marketing, reporting to Judith Robertson, Aerie’s Chief Commercial Officer."
AERI,AERI:US,BBG001KJ7WJ5,Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate,2017-08-25 16:44:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pl660jolxgo/ultragenyx-files-bla-to-fda-for-hypophosphatemia-candidate-cm837231,Ultragenyx Pharmaceutical Inc RARE along with Japanese partner Kyowa Hakko Kirin Co Ltd announced filing of a biologics license application BLA to the FDA for its pipeline candidate burosumab KRN23 to treat patients with X linked hypophosphatemia XLH The FDA informed that a decision
AERI,AERI:US,BBG001KJ7WJ5,Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate,2017-08-25 14:23:02 +0000,https://finance.yahoo.com/news/ultragenyx-files-bla-fda-hypophosphatemia-142302575.html?.tsrc=rss,Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.
AERI,AERI:US,BBG001KJ7WJ5,Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data,2017-08-23 22:38:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q8SuS9Vcn5M/ultragenyx-rare-posts-disappointing-phase-iii-ace-er-data-cm836242,Ultragenyx Pharmaceutical Inc RARE announced discouraging top line data from a phase III study evaluating its investigational Ace ER aceneuramic acid extended release on patients with GNE Myopathy GNEM a progressive muscle wasting disorder As a result the company plans to discontinue
AERI,AERI:US,BBG001KJ7WJ5,Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data,2017-08-23 20:06:08 +0000,https://finance.yahoo.com/news/ultragenyx-rare-posts-disappointing-phase-200608109.html?.tsrc=rss,Ultragenyx (RARE) plans to discontinue further clinical development of Ace-ER after posting discouraging data from a phase III study that evaluated the candidate on patients with GNE Myopathy.
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-22 12:02:31 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120231126.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,"Gainers & Losers Of Aug.17: GTHX, CDTX, KMDA, ACHC, EDIT...",2017-08-17 21:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uJyfZoXKKfc/gainers--losers-of-aug17-gthx-cdtx-kmda-achc-edit-20170817-01175,"Gainers & Losers Of Aug.17: GTHX, CDTX, KMDA, ACHC, EDIT..."
AERI,AERI:US,BBG001KJ7WJ5,"Noteworthy Thursday Option Activity: LSTR, CACC, AERI",2017-08-17 19:53:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NAA7AG3VUHs/noteworthy-thursday-option-activity-lstr-cacc-aeri-cm833532,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Landstar System Inc Symbol LSTR where a total of 2 637 contracts have traded so far representing approximately 263 700 underlying shares That amounts to about 84 4 of LSTR
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-17 12:04:38 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120438464.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-16 12:03:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120351214.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-14 12:04:00 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120400877.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons",2017-08-14 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-isabel-103000135.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Isabel Moredo, PharmD, as Eastern Regional Director of Medical Science Liaisons, reporting to Welyn Bui, PharmD, Aerie’s National Director of Medical ..."
AERI,AERI:US,BBG001KJ7WJ5,Edited Transcript of AERI earnings conference call or presentation 1-Aug-17 9:00pm GMT,2017-08-13 00:15:54 +0000,https://finance.yahoo.com/news/edited-transcript-aeri-earnings-conference-010331092.html?.tsrc=rss,Q2 2017 Aerie Pharmaceuticals Inc Earnings Call
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-11 12:02:58 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120258279.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,Aerie expanding RTP space as it looks to commercialization,2017-08-10 20:38:12 +0000,http://finance.yahoo.com/r/4c95e02e-1f0e-3cc6-9e6b-6f4597b1564d/aerie-expanding-rtp-space-as-it-looks-to.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Duke University spinout Aerie Pharmaceuticals (AERI) is expanding its Research Triangle Park space as it looks to commercialization.  Aerie has expanded by 13,385 square feet to a total of 32,586 square feet at the Imperial Center on Emperor Boulevard, according to an announcement from landlord Longfellow Real Estate Partners.  The expanded facility will include additional lab and office space."
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-10 12:03:00 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120300020.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,Health Care Sector Update for 08/09/2017: AERI,2017-08-09 13:54:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-QpZyZvfXQ/health-care-sector-update-for-08092017-aeri-cm829334,Top Health care stocks Top Health care stocks JNJ 0 2 JNJ 0 2 PFE 0 1 PFE 0 1 ABT 0 2 ABT 0 2 MRK 0 2 MRK 0 2 AMGN 0 5 AMGN 0 5 Health care shares were mixed in early trade on Wednesday Health care shares were mixed in early trade on Wednesday In health care stocks
AERI,AERI:US,BBG001KJ7WJ5,See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.,2017-08-09 12:02:58 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120258194.html?.tsrc=rss,Aerie Pharmaceuticals Inc NASDAQ NMS:AERI
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Comments on Notification from Contract Manufacturer,2017-08-08 20:01:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-comments-notification-contract-200100406.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has received notification by its contract drug product manufacturer that the contract manufacturer has received a Complete Response Letter from ..."
AERI,AERI:US,BBG001KJ7WJ5,Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2%,2017-08-07 14:42:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VEn7-ZiDyfA/spectrum-pharmaceuticals-sppi-looks-good-stock-jumps-222-cm828038,Spectrum Pharmaceuticals Inc SPPI was a big mover last session as the company saw its shares jump a little above 22 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend for the company as the stock is
AERI,AERI:US,BBG001KJ7WJ5,Spectrum Pharmaceuticals (SPPI) Looks Good: Stock Jumps 22.2%,2017-08-07 12:20:12 +0000,https://finance.yahoo.com/news/spectrum-pharmaceuticals-sppi-looks-good-122012692.html?.tsrc=rss,"Spectrum Pharmaceuticals, Inc. (SPPI) shares jumped a little above 22% in the last trading session."
AERI,AERI:US,BBG001KJ7WJ5,New Strong Buy Stocks for August 2nd,2017-08-02 16:01:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9q5pjAUoso/new-strong-buy-stocks-for-august-2nd-cm825884,Here are 5 stocks added to the Zacks Rank 1 Strong Buy List today Aerie Pharmaceuticals Inc AERI This clinical stage pharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings gaining 2 5 over the last 30 days Aerie Pharmaceuticals
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2,2017-08-02 16:00:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rV6wVStSKyA/aerie-aeri-reports-narrower-than-expected-loss-in-q2-cm825758,Aerie Pharmaceuticals Inc AERI posted second quarter 2017 loss of 82 cents per share including stock based compensation narrower than the Zacks Consensus Estimate of a loss of 84 cents and the year ago loss of 87 cents Being a development stage company Aerie has not generated
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2,2017-08-02 14:10:02 +0000,https://finance.yahoo.com/news/aerie-aeri-reports-narrower-expected-141002793.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc.&apos;s (AERI) narrower-than-expected loss in the second quarter was encouraging."
AERI,AERI:US,BBG001KJ7WJ5,New Strong Buy Stocks for August 2nd,2017-08-02 13:23:01 +0000,https://finance.yahoo.com/news/strong-buy-stocks-august-2nd-132301843.html?.tsrc=rss,New Strong Buy Stocks for August 2nd
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference,2017-08-02 11:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-present-canaccord-genuity-113000451.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on Wednesday, August 9, 2017 at 3:30 p.m...."
AERI,AERI:US,BBG001KJ7WJ5,Featured Company News – Aerie Pharma to Collaborate with DSM Focused on Technology to Deliver Aerie Compounds to Treat Retinal Diseases,2017-08-02 11:20:00 +0000,https://finance.yahoo.com/news/featured-company-news-aerie-pharma-112000029.html?.tsrc=rss,"Research Desk Line-up: Merck Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aerie Pharmaceuticals, ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 2Q loss,2017-08-02 01:54:29 +0000,https://finance.yahoo.com/news/aerie-reports-2q-loss-205339444.html?.tsrc=rss,"On a per-share basis, the Irvine, California-based company said it had a loss of 82 cents. Losses, adjusted for stock option expense, came to 63 cents per share. The results exceeded Wall Street expectations. ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update,2017-08-01 20:01:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-reports-second-quarter-200100173.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2017, along with a general business update."
AERI,AERI:US,BBG001KJ7WJ5,"Investor Network: Aerie Pharmaceuticals, Inc. to Host Earnings Call",2017-08-01 16:15:00 +0000,https://finance.yahoo.com/news/investor-network-aerie-pharmaceuticals-inc-161500236.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 1, 2017 / Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) will be discussing their earnings results in their Q2 Earnings Call to be held August 1, 2017 at 5:00 PM Eastern ..."
AERI,AERI:US,BBG001KJ7WJ5,"Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY",2017-07-31 14:30:02 +0000,https://finance.yahoo.com/news/drug-stocks-q2-earnings-releases-143002654.html?.tsrc=rss,The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Enters into Collaboration Agreement with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases such as Wet AMD,2017-07-31 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-enters-collaboration-agreement-103000636.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has entered into a collaborative research, development and license agreement with DSM."
AERI,AERI:US,BBG001KJ7WJ5,What's in the Cards for Aerie (AERI) This Earnings Season?,2017-07-27 20:57:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3x3f2pyEOnQ/whats-in-the-cards-for-aerie-aeri-this-earnings-season-cm822823,Aerie Pharmaceuticals Inc AERI is scheduled to second quarter 2017 results on Aug 1 Last quarter the company missed expectations by 2 70 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected loss in the four
AERI,AERI:US,BBG001KJ7WJ5,What&apos;s in the Cards for Aerie (AERI) This Earnings Season?,2017-07-27 18:58:06 +0000,https://finance.yahoo.com/news/apos-cards-aerie-aeri-earnings-185806175.html?.tsrc=rss,Aerie Pharmaceuticals (AERI) is expected to throw light on updates on Rhopressa during its second-quarter earnings call on Aug 1.
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017",2017-07-26 11:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announce-second-quarter-113000615.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , , announced today that its second quarter 2017 financial results will be released after the market closes on Tuesday, August 1, 2017."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Richard A. Halprin as Director of Professional Affairs,2017-07-25 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-richard-103000077.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Richard A."
AERI,AERI:US,BBG001KJ7WJ5,New Strong Buy Stocks for July 24th,2017-07-24 18:06:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ikj-bOM7MEo/new-strong-buy-stocks-for-july-24th-cm820432,Here are 5 stocks added to the Zacks Rank 1 Strong Buy List today Aerie Pharmaceuticals Inc AERI This clinical stage pharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2 5 over the last 30 days Aerie Pharmaceuticals
AERI,AERI:US,BBG001KJ7WJ5,New Strong Buy Stocks for July 24th,2017-07-24 15:16:03 +0000,https://finance.yahoo.com/news/strong-buy-stocks-july-24th-151603453.html?.tsrc=rss,New Strong Buy Stocks for July 24th
AERI,AERI:US,BBG001KJ7WJ5,"Commit To Purchase Aerie Pharmaceuticals At $40, Earn 13% Using Options",2017-07-21 19:06:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gPrSXk0IgjE/commit-to-purchase-aerie-pharmaceuticals-at-40-earn-13-using-options-cm819514,Investors eyeing a purchase of Aerie Pharmaceuticals Inc Symbol AERI stock but cautious about paying the going market price of 57 88 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
AERI,AERI:US,BBG001KJ7WJ5,"SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz",2017-07-20 02:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mEEsv6xa56w/srpt-soars-on-q2-results--outlook-aeris-mercury1-does-an-encore-alim-abuzz-20170720-00099,"SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results,2017-07-19 20:01:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-roclatan-200100471.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™...."
AERI,AERI:US,BBG001KJ7WJ5,Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4%,2017-06-29 14:08:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fXao87n0Mng/esperion-therapeutics-espr-looks-good-stock-gains-104-cm809813,Esperion Therapeutics Inc ESPR was a big mover last session as the company saw its shares jump a little above 10 on the day The move came after a regulatory pathway for its cholesterol lowering combination was approved by the Food and Drug Administration Also this led to far more
AERI,AERI:US,BBG001KJ7WJ5,Immune Design (IMDZ) Shows Strength: Stock Moves 6.2% Higher,2017-06-27 13:53:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9Xwk6g7qgeg/immune-design-imdz-shows-strength-stock-moves-62-higher-cm808760,Immune Design Corp IMDZ was a big mover last session as the company saw its shares rise a little above 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up over
AERI,AERI:US,BBG001KJ7WJ5,Can The Uptrend Continue for Aerie Pharmaceuticals (AERI)?,2017-06-07 10:17:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zG4Dsms3gXM/can-the-uptrend-continue-for-aerie-pharmaceuticals-aeri-cm799783,Investors certainly have to be happy with Aerie Pharmaceuticals Inc AERI and its short term performance After all the stock has jumped by 35 9 in the past 4 weeks and it is also above its 20 Day Simple Moving Average as well This is certainly a good trend but investors are probably
AERI,AERI:US,BBG001KJ7WJ5,Can The Uptrend Continue for Aerie Pharmaceuticals (AERI)?,2017-06-07 08:16:08 +0000,https://finance.yahoo.com/news/uptrend-continue-aerie-pharmaceuticals-aeri-081608352.html?.tsrc=rss,Investors certainly have to be happy with Aerie Pharmaceuticals Inc (AERI) and its short term performance
AERI,AERI:US,BBG001KJ7WJ5,Radius Health (RDUS) Looks Good: Stock Adds 10.5% in Session,2017-06-06 14:05:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vQCEHH3sMnY/radius-health-rdus-looks-good-stock-adds-105-in-session-cm799168,Radius Health Inc RDUS was a big mover last session as the company saw its shares jump above 10 on the day The move came after the company posted data from a phase 1 clinical trial Also this led to far more shares changing hands than in a normal session This breaks the recent trend
AERI,AERI:US,BBG001KJ7WJ5,Why Is Aerie (AERI) Up 40.4% Since the Last Earnings Report?,2017-06-02 09:33:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PNC2cjw6Xzs/why-is-aerie-aeri-up-404-since-the-last-earnings-report-cm797778,It has been about a month since the last earnings report for Aerie Pharmaceuticals Inc AERI Shares have added about 40 4 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback
AERI,AERI:US,BBG001KJ7WJ5,Why Is Aerie (AERI) Up 40.4% Since the Last Earnings Report?,2017-06-02 07:12:07 +0000,https://finance.yahoo.com/news/why-aerie-aeri-40-4-071207677.html?.tsrc=rss,Aerie (AERI) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at Two Investor Conferences in June,2017-06-01 11:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-present-two-investor-113000118.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, and Richard Rubino, Chief Financial Officer, will attend the following conferences in June."
AERI,AERI:US,BBG001KJ7WJ5,MEI Pharma (MEIP) Shows Strength: Stock Moves 7.6% Higher,2017-05-30 13:37:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XS_TM0AFCA0/mei-pharma-meip-shows-strength-stock-moves-76-higher-cm796142,MEI Pharma Inc MEIP was a big mover last session as the company saw its shares rise nearly 8 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up over 33 in
AERI,AERI:US,BBG001KJ7WJ5,"Biotech Movers: Immunomedics, Aerie, Exelixis",2017-05-26 13:33:00 +0000,http://finance.yahoo.com/r/d75e5b28-21b4-33f7-8a5f-053b56380e02/biotech-movers-immunomedics-aerie-exelixis.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday."
AERI,AERI:US,BBG001KJ7WJ5,"Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data",2017-05-26 12:08:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-label-expansion-120812582.html?.tsrc=rss,Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
AERI,AERI:US,BBG001KJ7WJ5,BioCryst and Aerie Pharmaceuticals' Shares Swell on Positive Study Results,2017-05-26 12:00:00 +0000,https://finance.yahoo.com/news/biocryst-aerie-pharmaceuticals-shares-swell-120000014.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 26, 2017 / BioCryst's shares skyrocketed on Thursday with trading volume significantly higher than usual after the company revealed positive results from a mid-stage close ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering,2017-05-26 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-raises-125-million-103000593.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has priced its registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $53.75 per share...."
AERI,AERI:US,BBG001KJ7WJ5,"Why Sears Holdings, Aerie Pharmaceuticals, and Guess? Jumped Today",2017-05-25 22:32:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WcOmhagAyUQ/why-sears-holdings-aerie-pharmaceuticals-and-guess-jumped-today-cm794897,The stock market celebrated Thursday by sending the S amp P 500 to a record high Gains for the major benchmarks varied from a third of a percent to three quarters of a percent as investors were generally pleased with signs that the consumer economy in the U S continues to move
AERI,AERI:US,BBG001KJ7WJ5,"Gainers & Losers Of May 25: AERI, BCRX, NEOT, SNDX, SYRS...",2017-05-25 20:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JxNyMg2wkXU/gainers--losers-of-may-25-aeri-bcrx-neot-sndx-syrs-20170525-01308,"Gainers & Losers Of May 25: AERI, BCRX, NEOT, SNDX, SYRS..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie's Ophthalmic Candidate Positive in Registration Trial,2017-05-25 20:32:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2HJ6r5hLjoI/aeries-ophthalmic-candidate-positive-in-registration-trial-cm794820,Aerie Pharmaceuticals Inc AERI announced positive primary efficacy results of the 90 day phase III registration trial Mercury 2 for its pipeline candidate Roclatan We note that Aerie has outperformed the Zacks classified Medical Drugs industry in the last 12 months The stock
AERI,AERI:US,BBG001KJ7WJ5,"Why Sears Holdings, Aerie Pharmaceuticals, and Guess? Jumped Today",2017-05-25 20:32:00 +0000,http://finance.yahoo.com/r/eb6a5565-f554-349a-b4dc-e21c709298ed/why-sears-holdings-aerie-pharmaceuticals-and-guess.aspx?yptr=yahoo&.tsrc=rss,These stocks led the market to record highs. Find out why.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Public Offering of Common Stock,2017-05-25 20:02:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-public-offering-200200085.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock."
AERI,AERI:US,BBG001KJ7WJ5,"Stocks rise for Aerie, BioCryst following positive trial results",2017-05-25 18:55:10 +0000,http://finance.yahoo.com/r/4212b831-555c-3577-9e04-c2f98451c086/stocks-rise-for-aerie-biocryst-following-positive.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Duke University spinout Aerie Pharmaceuticals’ (AERI) as well as Durham-based BioCryst Pharmaceuticals (BCRX) both saw stock prices jump Thursday on the heels of positive trial results.  Shares of both companies were up about 30 percent Thursday afternoon, with shares of Aerie trading just under $53 and shares of BioCryst trading close to $7.  Late Wednesday, Aerie announced positive Phase 2 trial results for glaucoma product Roclatan."
AERI,AERI:US,BBG001KJ7WJ5,Why Aerie Pharmaceuticals Inc. Is Skyrocketing Today,2017-05-25 18:33:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IREB83w2NfI/why-aerie-pharmaceuticals-inc-is-skyrocketing-today-cm794732,What happened In response to the company reporting data from its late stage Mercury 2 trial shares of Aerie Pharmaceuticals NASDAQ AERI a clinical stage biotech focused on diseases of the eye 160 rose by 33 as of 11 45 a m EDT on Thursday So what Aerie s
AERI,AERI:US,BBG001KJ7WJ5,Aerie&apos;s Ophthalmic Candidate Positive in Registration Trial,2017-05-25 18:13:06 +0000,https://finance.yahoo.com/news/aerie-apos-ophthalmic-candidate-positive-181306598.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan."
AERI,AERI:US,BBG001KJ7WJ5,"Health Care Sector Update for 05/25/2017: AERI,BCRX,CORI",2017-05-25 17:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KoHv53rNHss/health-care-sector-update-for-05252017-aeribcrxcori-cm794720,Top Health Care StocksTop Health Care Stocks JNJ 0 22 JNJ 0 22 PFE 0 01 PFE 0 01 ABT 0 55 ABT 0 55 MRK 0 28 MRK 0 28 AMGN 0 91 AMGN 0 91 Health care stocks were keeping pace with much of the broader U S markets Thursday with the NYSE Health Care Index climbing almost 0 3
AERI,AERI:US,BBG001KJ7WJ5,Why Aerie Pharmaceuticals Inc. Is Skyrocketing Today,2017-05-25 16:39:00 +0000,http://finance.yahoo.com/r/6fcfb7aa-2575-39fe-8bbd-f7b5ec50c84e/why-aerie-pharmaceuticals-inc-is-skyrocketing-toda.aspx?yptr=yahoo&.tsrc=rss,Investors cheer the release of upbeat clinical results from an important phase 3 trial.
AERI,AERI:US,BBG001KJ7WJ5,Story Stocks from Briefing.com,2017-05-25 16:09:40 +0000,https://finance.yahoo.com/news/story-stocks-briefing-com-175403381.html?.tsrc=rss,Story Stocks from Briefing.com
AERI,AERI:US,BBG001KJ7WJ5,Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring,2017-05-25 13:37:00 +0000,http://finance.yahoo.com/r/4ca490ff-7b9e-3b6d-82f5-b5b737589f5d/biotech-movers-positive-phase-three-results-for-roclatan-send-aerie-shares-soaring.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday."
AERI,AERI:US,BBG001KJ7WJ5,"Pre-Market Most Active for May 25, 2017 :  BBY, QQQ, CWH, ANF, BP, AERI, SNY, NTEST, BCRX, XIV, SNDX, NFLX",2017-05-25 13:00:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FqsrkWF7yzs/pre-market-most-active-for-may-25-2017-bby-qqq-cwh-anf-bp-aeri-sny-ntest-bcrx-xiv-sndx-nflx-cm794361,The NASDAQ 100 Pre Market Indicator is up 12 63 to 5 742 93 The total Pre Market volume is currently 5 043 674 shares traded The following are the most active stocks for the pre market session Best Buy Co Inc BBY is 6 28 at 56 70 with 601 133 shares traded
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Inc. (AERI) Has Leaped To A New High On Study Results,2017-05-25 09:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TU8vTwSd5as/aerie-pharmaceuticals-inc-aeri-has-leaped-to-a-new-high-on-study-results-20170525-00700,Aerie Pharmaceuticals Inc. (AERI) Has Leaped To A New High On Study Results
AERI,AERI:US,BBG001KJ7WJ5,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI",2017-05-25 01:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ofrEaaE3wzk/aeri-is-awesome-gwph-abuzz-fda-panel-nod-for-pbyi-20170525-00028,"AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops,2017-05-24 20:30:04 +0000,http://finance.yahoo.com/r/a16fd80c-9f9b-3b39-a4e2-ff108e7ec148/Story.aspx?guid=978E6FAB-D45C-4591-8985-20FAADF3D501&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Aerie Pharmaceuticals Inc. shares surged as much as 32% in after hours trade Wednesday after the company said its eye drops intended for glaucoma had positive results in a late-stage clinical trial. If ...
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results,2017-05-24 20:01:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-roclatan-200100906.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful primary efficacy results of the Company’s 90-day Phase 3 “Mercury 2” registration trial for its fixed-dose combination product candidate, ..."
AERI,AERI:US,BBG001KJ7WJ5,ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher,2017-05-19 14:17:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/van5aUDQ6as/immunogen-imgn-shows-strength-stock-up-142-higher-cm791789,ImmunoGen Inc IMGN was a big mover last session as the company saw its shares jump above 14 on the day The upside took place after it released abstracts for the current year s American Society of Clinical Oncology ASCO meeting followed by a press release of the updated data This
AERI,AERI:US,BBG001KJ7WJ5,GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7%,2017-05-19 14:17:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1tSkThhiaQg/glycomimetics-glyc-shows-strength-stock-jumps-987-cm791915,GlycoMimetics Inc GLYC was a big mover last session as the company saw its shares skyrocketed to almost 99 on the day The upside occurred after the company declared that the FDA designated one of its drugs as a Breakthrough Therapy 160 Also this led to far more shares changing hands
AERI,AERI:US,BBG001KJ7WJ5,GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7%,2017-05-19 12:35:12 +0000,https://finance.yahoo.com/news/glycomimetics-glyc-shows-strength-stock-123512375.html?.tsrc=rss,"GlycoMimetics, Inc. (GLYC) shares skyrocketed to almost 99% in the last trading session."
AERI,AERI:US,BBG001KJ7WJ5,ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher,2017-05-19 12:20:12 +0000,https://finance.yahoo.com/news/immunogen-imgn-shows-strength-stock-122012119.html?.tsrc=rss,"ImmunoGen, Inc. (IMGN) shares jumped above 14% in the last trading session."
AERI,AERI:US,BBG001KJ7WJ5,Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher,2017-05-18 14:17:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VYWPFlYdx9U/cardiome-pharma-crme-looks-good-stock-moves-61-higher-cm791146,Cardiome Pharma Corp CRME was a big mover last session as the company saw its shares rise a little above 6 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up
AERI,AERI:US,BBG001KJ7WJ5,Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher,2017-05-18 12:20:12 +0000,https://finance.yahoo.com/news/cardiome-pharma-crme-looks-good-122012208.html?.tsrc=rss,Cardiome Pharma Corp. (CRME) shares rose a little above 6% in the last trading session.
AERI,AERI:US,BBG001KJ7WJ5,Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review,2017-05-17 00:15:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZRwzhXEv7Y4/aeries-aeri-rhopressa-nda-sufficient-for-fda-review-cm790285,Aerie Pharmaceuticals Inc AERI announced that it has received notification from the FDA about the completion of the initial 60 day review of the new drug application NDA for Rhopressa The FDA determined that the application is sufficiently complete and can undergo a substantive
AERI,AERI:US,BBG001KJ7WJ5,Aerie&apos;s (AERI) Rhopressa NDA Sufficient for FDA Review,2017-05-16 22:13:10 +0000,https://finance.yahoo.com/news/aerie-apos-aeri-rhopressa-nda-221310940.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces New Hires,2017-05-16 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-hires-103000953.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointments of Jessica Crespo, CPA, as Director of Accounting, Minh Lu as Director of Supply Chain, and Lorcan O’Toole as Operations Director for the Aerie plant ..."
AERI,AERI:US,BBG001KJ7WJ5,Are Options Traders Betting on a Big Move in Aerie Pharmaceuticals (AERI) Stock?,2017-05-15 14:18:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a1x3R9TlbaE/are-options-traders-betting-on-a-big-move-in-aerie-pharmaceuticals-aeri-stock-cm789230,Investors in Aerie Pharmaceuticals Inc AERI need to pay close attention to the stock based on moves in the options market lately That is because the May 19th 2017 35 Put had some of the highest implied volatility of all equity options today What is Implied Volatility
AERI,AERI:US,BBG001KJ7WJ5,Aerie Bucking The Store Closure Trend,2017-05-15 12:52:00 +0000,http://finance.yahoo.com/r/3c1b07c7-2983-3090-aa95-ee42909b4c15/aerie-bucking-the-store-closure-trend?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,Declining mall traffic and low prices offered by fast fashion retailers have been crushing apparel retailers. One notable exception has been American Eagle's Aerie brand.
AERI,AERI:US,BBG001KJ7WJ5,Are Options Traders Betting on a Big Move in Aerie Pharmaceuticals (AERI) Stock?,2017-05-15 12:47:12 +0000,https://finance.yahoo.com/news/options-traders-betting-big-move-124712777.html?.tsrc=rss,Investors in Aerie Pharmaceuticals (AERI) need to pay close attention to the stock based on moves in the options market lately.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa™ (netarsudil ophthalmic solution) 0.02%,2017-05-15 10:30:00 +0000,https://finance.yahoo.com/news/aerie-pharmaceuticals-announces-fda-acceptance-103000697.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported that it has received notification from the U.S."
AERI,AERI:US,BBG001KJ7WJ5,Blog Coverage: Merck Receives European Commission Approval for the Treatment of Hodgkin Lymphoma,2017-05-08 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-merck-receives-european-121500278.html?.tsrc=rss,"Upcoming AWS Coverage on Aerie Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / May 8, 2017 / Active Wall St. blog coverage looks at the headline from Merck & Co., Inc. (NYSE: MRK ) as the ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up",2017-05-03 20:50:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_0qDJwaJURY/aerie-aeri-posts-wider-than-expected-q1-loss-expenses-up-cm783562,Aerie Pharmaceuticals Inc AERI posted first quarter 2017 loss of 76 cents per share including stock based compensation wider than the Zacks Consensus Estimate of a loss of 74 cents but narrower than the year ago loss of 85 cents Being a development stage company Aerie has not
AERI,AERI:US,BBG001KJ7WJ5,"Notable Wednesday Option Activity: GRA, AERI, GILD",2017-05-03 19:50:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hL5_8YHgikE/notable-wednesday-option-activity-gra-aeri-gild-cm783655,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Grace amp Co Symbol GRA where a total volume of 8 396 contracts has been traded thus far today a contract volume which is representative of approximately 839 600
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up",2017-05-03 18:34:06 +0000,http://finance.yahoo.com/news/aerie-aeri-posts-wider-expected-183406691.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) posted first-quarter 2017 loss of 76 cents per share (including stock-based compensation), wider than the Zacks Consensus Estimate of a loss of 74 cents."
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 1Q loss,2017-05-02 21:28:28 +0000,http://finance.yahoo.com/news/aerie-reports-1q-loss-212828232.html?.tsrc=rss,"The Irvine, California-based company said it had a loss of 76 cents per share. Losses, adjusted for stock option expense, came to 62 cents per share. The results surpassed Wall Street expectations. The ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update,2017-05-02 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-first-quarter-200100675.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2017, along with a general business update."
AERI,AERI:US,BBG001KJ7WJ5,"Investor Network: Aerie Pharmaceuticals, Inc. to Host Earnings Call",2017-05-02 13:05:00 +0000,http://finance.yahoo.com/news/investor-network-aerie-pharmaceuticals-inc-130500024.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 2, 2017 / Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) will be discussing their earnings results in their Q1 Earnings Call to be held May 2, 2017 at 5:00 PM Eastern Time. ..."
AERI,AERI:US,BBG001KJ7WJ5,What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?,2017-04-26 15:10:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JpijALQScg/what-awaits-aerie-pharmaceuticals-aeri-in-q1-earnings-cm779429,Aerie Pharmaceuticals Inc AERI is scheduled to report first quarter 2017 results on May 2 Last quarter the company missed expectations by 33 85 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected loss in the
AERI,AERI:US,BBG001KJ7WJ5,What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?,2017-04-26 13:04:01 +0000,http://finance.yahoo.com/news/awaits-aerie-pharmaceuticals-aeri-q1-130401995.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017",2017-04-25 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announce-first-quarter-113000238.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , , announced today that its first quarter 2017 financial results will be released after the market closes on Tuesday, May 2, 2017."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance,2017-04-24 10:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-raymond-103000345.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Raymond S."
AERI,AERI:US,BBG001KJ7WJ5,"Friday 4/21 Insider Buying Report: JPM, AERI",2017-04-21 16:05:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TmE1w14l714/friday-421-insider-buying-report-jpm-aeri-cm777103,As the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy they expect to make money So let s look at two noteworthy recent insider buys At JPMorgan Chase JPM a filing with the SEC revealed that on Wednesday Director James
AERI,AERI:US,BBG001KJ7WJ5,Implied Volatility Surging for Aerie Pharmaceuticals (AERI) Stock Options,2017-04-19 15:08:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w-DXIXYaHk8/implied-volatility-surging-for-aerie-pharmaceuticals-aeri-stock-options-cm775791,Investors in Aerie Pharmaceuticals Inc AERI need to pay close attention to the stock based on moves in the options market lately That is because the April 21st 2017 50 Call had some of the highest implied volatility of all equity options today What is Implied Volatility
AERI,AERI:US,BBG001KJ7WJ5,Implied Volatility Surging for Aerie Pharmaceuticals (AERI) Stock Options,2017-04-19 12:47:12 +0000,http://finance.yahoo.com/news/implied-volatility-surging-aerie-pharmaceuticals-124712680.html?.tsrc=rss,Aerie Pharmaceuticals (AERI) warrants investors&apos; attention based on moves in the options market lately.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Reports Positive Data on Ophthalmic Drug Rhopressa,2017-04-13 13:58:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h2rWdBvCVSY/aerie-reports-positive-data-on-ophthalmic-drug-rhopressa-cm773673,Aerie Pharmaceuticals Inc AERI reported encouraging six month top line safety and efficacy results from the phase III trial ROCKET 4 on lead product candidate Rhopressa We note that Aerie is evaluating Rhopressa a novel once daily eye drop for its ability to lower intraocular
AERI,AERI:US,BBG001KJ7WJ5,Aerie Reports Positive Data on Ophthalmic Drug Rhopressa,2017-04-13 11:54:11 +0000,http://finance.yahoo.com/news/aerie-reports-positive-data-ophthalmic-115411620.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa."
AERI,AERI:US,BBG001KJ7WJ5,"AERI's Rocket Hits Target, ENTL Gets FDA Nod, NOVN Jumps On Positive Trial Data",2017-04-13 02:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n95SzSbHyvU/aeris-rocket-hits-target-entl-gets-fda-nod-novn-jumps-on-positive-trial-data-20170413-00053,"AERI's Rocket Hits Target, ENTL Gets FDA Nod, NOVN Jumps On Positive Trial Data"
AERI,AERI:US,BBG001KJ7WJ5,"After-hours buzz: PIR, HBI & AERI",2017-04-12 22:27:31 +0000,http://finance.yahoo.com/r/f13835ce-47f6-32d6-b00b-8c8ab49712d3/104401282?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104401282&yptr=yahoo&.tsrc=rss,See which stocks are posting big moves after the bell.
AERI,AERI:US,BBG001KJ7WJ5,"After-hours buzz: PIR, HBI & AERI",2017-04-12 22:27:31 +0000,http://finance.yahoo.com/news/hours-buzz-pir-hbi-aeri-222731430.html?.tsrc=rss,See which stocks are posting big moves after the bell.
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%,2017-04-12 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-rocket-200100789.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported the successful six-month topline safety and efficacy results of its Rocket 4 Phase 3 clinical trial for product candidate RhopressaTM, a novel once-daily eye drop being ..."
AERI,AERI:US,BBG001KJ7WJ5,3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich,2017-04-11 12:57:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HtF7104z8wk/3-clinical-stage-biotech-stocks-that-could-be-about-to-strike-it-rich-cm772521,Axovant Sciences NYSE AXON Esperion Therapeutics NASDAQ ESPR and Aerie Pharmaceuticals NASDAQ AERI have late stage drugs in development that could catapult them to profitability in the next few years Will they overcome the odds and end up with billion
AERI,AERI:US,BBG001KJ7WJ5,3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich,2017-04-11 11:02:00 +0000,http://finance.yahoo.com/r/59447e8b-e604-3478-9bf4-9a4e94c3afc9/3-clinical-stage-biotech-stocks-that-could-be-abou.aspx?yptr=yahoo&.tsrc=rss,"Axovant Sciences, Esperion Therapeutics, and Aerie Pharmaceuticals are developing drugs targeting multibillion-dollar indications."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Expansion of Commercialization Team,2017-04-10 10:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-expansion-commercialization-103000542.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointments of new employees Gary Menichini as Vice President of Sales, Dale Seibt as Vice President of Market Access, and Gerry McKenzie as Vice President of Commercial ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Down 12.9% Since Earnings Report: Can It Rebound?,2017-04-07 13:57:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iMlHh_xDSOQ/aerie-aeri-down-129-since-earnings-report-can-it-rebound-cm771262,It has been about a month since the last earnings report for Aerie Pharmaceuticals Inc AERI Shares have lost about 12 9 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Down 12.9% Since Earnings Report: Can It Rebound?,2017-04-07 11:15:11 +0000,http://finance.yahoo.com/news/aerie-aeri-down-12-9-111511255.html?.tsrc=rss,Aerie (AERI) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
AERI,AERI:US,BBG001KJ7WJ5,Blog Coverage AstraZeneca's Lung Cancer Drug Received Full Approval from FDA,2017-04-03 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-astrazenecas-lung-cancer-121500840.html?.tsrc=rss,"Upcoming AWS Coverage on Aerie Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / April 3, 2017 / Active Wall St. blog coverage looks at the headline from AstraZeneca PLC (NYSE: AZN ) as the ..."
AERI,AERI:US,BBG001KJ7WJ5,Blog Coverage AstraZeneca's Lung Cancer Drug Received Full Approval from FDA,2017-04-03 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-astrazenecas-lung-cancer-121500840.html,"[Accesswire] - Upcoming AWS Coverage on Aerie Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / April 3, 2017 / Active Wall St. blog coverage looks at the headline from AstraZeneca PLC (NYSE: AZN ) as the ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference,2017-03-28 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-16th-annual-113000543.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 1:40 ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference,2017-03-28 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-16th-annual-113000543.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 at 1:40 ..."
AERI,AERI:US,BBG001KJ7WJ5,Blog Coverage Novartis Licences its Immunosenescence Drugs to PureTech Health,2017-03-27 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-licences-immunosenescence-121500265.html?.tsrc=rss,"Upcoming AWS Coverage on Aerie Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / March 27, 2017 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS ). PureTech ..."
AERI,AERI:US,BBG001KJ7WJ5,Blog Coverage Novartis Licences its Immunosenescence Drugs to PureTech Health,2017-03-27 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-licences-immunosenescence-121500265.html,"[Accesswire] - Upcoming AWS Coverage on Aerie Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / March 27, 2017 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS ). PureTech ..."
AERI,AERI:US,BBG001KJ7WJ5,Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA,2017-03-21 22:06:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YMC3vqWpZEM/valeants-vrx-glaucoma-candidate-gets-pdufa-date-from-fda-cm763794,Valeant Pharmaceuticals International Inc s VRX wholly owned subsidiary Bausch Lomb and Nicox S A announced that the FDA has set a PDUFA date of Aug 24 for its decision on the New Drug Application NDA for latanoprostene bunod ophthalmic solution 0 024 We note that
AERI,AERI:US,BBG001KJ7WJ5,Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA,2017-03-21 20:32:08 +0000,http://finance.yahoo.com/news/valeants-vrx-glaucoma-candidate-gets-203208726.html,Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA
AERI,AERI:US,BBG001KJ7WJ5,AERIE PHARMACEUTICALS INC Financials,2017-03-15 17:04:09 +0000,http://finance.yahoo.com/q/is?s=aeri,AERIE PHARMACEUTICALS INC Financials
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction",2017-03-13 14:07:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zDIHBZ1JcQI/aerie-resubmits-rhopressa-nda-roclatan-gains-traction-cm759899,We issued an updated research report on Aerie Pharmaceuticals Inc AERI on Mar 10 2016 Aerie Pharmaceuticals is a development stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye diseases Aerie s two lead
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction",2017-03-13 13:16:01 +0000,http://finance.yahoo.com/news/aerie-resubmits-rhopressa-nda-roclatan-131601071.html?.tsrc=rss,"Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction",2017-03-13 13:16:01 +0000,http://finance.yahoo.com/news/aerie-resubmits-rhopressa-nda-roclatan-131601071.html,"Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction"
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report",2017-03-09 21:37:49 +0000,http://biz.yahoo.com/e/170309/aeri10-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma downgraded by Raymond James,2017-03-09 12:25:53 +0000,http://finance.yahoo.com/q/ud?s=AERI,Aerie Pharma downgraded by Raymond James
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted",2017-03-08 22:13:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mudvyGdh2h4/aerie-aeri-q4-loss-widens-rhopressa-nda-resubmitted-cm758135,Aerie Pharmaceuticals Inc AERI posted fourth quarter 2016 loss of 87 cents per share including stock based compensation wider than both the Zacks Consensus Estimate of a loss of 65 cents and the year ago loss of 76 cents Being a development stage company Aerie has not generated
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted",2017-03-08 20:10:08 +0000,http://finance.yahoo.com/news/aerie-aeri-q4-loss-widens-201008177.html,"Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted",2017-03-08 20:10:08 +0000,http://finance.yahoo.com/news/aerie-aeri-q4-loss-widens-201008177.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents"
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 4Q loss,2017-03-07 21:39:52 +0000,http://sg.finance.yahoo.com/news/aerie-reports-4q-loss-213952015.html,Aerie reports 4Q loss
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 4Q loss,2017-03-07 21:39:52 +0000,http://finance.yahoo.com/news/aerie-reports-4q-loss-213952276.html?.tsrc=rss,"On a per-share basis, the Irvine, California-based company said it had a loss of 87 cents. Losses, adjusted for stock option expense, came to 72 cents per share. For the year, the company reported a loss ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2017-03-07 21:07:16 +0000,http://biz.yahoo.com/e/170307/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update,2017-03-07 21:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-fourth-quarter-210100964.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2016, along with a general business update."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update,2017-03-07 21:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-fourth-quarter-210100964.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2016, along with a general business update."
AERI,AERI:US,BBG001KJ7WJ5,"After-Hours Earnings Report for March 7, 2017 :  HRB, URBN, ABM, AERI, NCS, ALG, EDIT, NMBL, BOJA, AFAM, AVAV, RGNX",2017-03-07 19:56:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U4kauijgi9g/after-hours-earnings-report-for-march-7-2017-hrb-urbn-abm-aeri-ncs-alg-edit-nmbl-boja-afam-avav-rgnx-cm757416,The following companies are expected to report earnings after hours on 03 07 2017 Visit our Earnings Calendar for a full list of expected earnings releases H amp R Block Inc HRB is reporting for the quarter ending January 31 2017 The business
AERI,AERI:US,BBG001KJ7WJ5,Q4 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close,2017-03-07 12:07:02 +0000,http://biz.yahoo.com/research/earncal/20170307.html?t=aeri,Q4 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close
AERI,AERI:US,BBG001KJ7WJ5,4 Small-Cap Biotech Stars,2017-03-05 19:00:00 +0000,http://finance.yahoo.com/r/aa88c30f-8494-3297-8d84-e7712b7a3bfb/4-small-cap-biotech-stars?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"I'm still enthusiastic about the sector, but it is critical to also be prudent."
AERI,AERI:US,BBG001KJ7WJ5,4 Small-Cap Biotech Stars,2017-03-05 19:00:00 +0000,http://realmoney.thestreet.com/articles/03/05/2017/4-small-cap-biotech-stars?puc=yahoo&cm_ven=YAHOO,4 Small-Cap Biotech Stars
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at Three Investor Conferences in March,2017-03-02 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-three-investor-123000002.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in March."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at Three Investor Conferences in March,2017-03-02 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-three-investor-123000002.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that company management will present at the following conferences in March."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-02 01:12:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xVea_hJVif8/aerie-pharmaceuticals-aeri-q4-earnings-what-to-expect-cm755162,Aerie Pharmaceuticals Inc AERI is expected to report fourth quarter 2016 results on Mar 7 Last quarter the company recorded a negative earnings surprise of 15 71 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-01 22:42:10 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-aeri-q4-earnings-224210249.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?,2017-03-01 22:42:10 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-aeri-q4-earnings-224210249.html,Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2017-03-01 11:36:49 +0000,http://biz.yahoo.com/e/170301/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,"6:31 am Aerie Pharma resubmits its NDA for Rhopressa to the FDA after notification by its contract drug product manufacturer that the vendor's Tampa, Florida facility is now ready for pre-approval inspection",2017-03-01 11:31:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#aeri,"6:31 am Aerie Pharma resubmits its NDA for Rhopressa to the FDA after notification by its contract drug product manufacturer that the vendor's Tampa, Florida facility is now ready for pre-approval inspection"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%,2017-03-01 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-resubmission-nda-113000712.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that on February 28, 2017 it resubmitted its NDA for RhopressaTM to the FDA after notification by its contract drug product manufacturer that the vendor’s Tampa, Florida ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%,2017-03-01 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-resubmission-nda-113000712.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that on February 28, 2017 it resubmitted its NDA for RhopressaTM to the FDA after notification by its contract drug product manufacturer that the vendor’s Tampa, Florida ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017",2017-02-27 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announce-fourth-quarter-123000872.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , , announced today that its fourth quarter and year end 2016 financial results will be released after the market closes on Tuesday, March 7, 2017."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017",2017-02-27 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announce-fourth-quarter-123000872.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , , announced today that its fourth quarter and year end 2016 financial results will be released after the market closes on Tuesday, March 7, 2017."
AERI,AERI:US,BBG001KJ7WJ5,"Noteworthy Wednesday Option Activity: GBT, JACK, AERI",2017-02-22 16:51:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RDLMl8q-9MI/noteworthy-wednesday-option-activity-gbt-jack-aeri-cm751402,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Global Blood Therapeutics Inc Symbol GBT where a total of 5 651 contracts have traded so far representing approximately 565 100 underlying shares That amounts to about 65 1 of GBT
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference,2017-02-15 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-rbc-capital-123000480.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer, will present in a fireside chat discussion at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference,2017-02-15 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-rbc-capital-123000480.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer, will present in a fireside chat discussion at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, ..."
AERI,AERI:US,BBG001KJ7WJ5,Post Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates,2017-02-10 13:15:00 +0000,http://finance.yahoo.com/news/post-earnings-coverage-eli-lillys-131500192.html?.tsrc=rss,"Upcoming AWS Coverage on Aerie Pharmaceuticals NEW YORK, NY / ACCESSWIRE / February 10, 2017 / Active Wall St. announces its post-earnings coverage on Eli Lilly and Co. (NYSE: LLY ). The Company reported ..."
AERI,AERI:US,BBG001KJ7WJ5,Post Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates,2017-02-10 13:15:00 +0000,http://finance.yahoo.com/news/post-earnings-coverage-eli-lillys-131500192.html,"[Accesswire] - Upcoming AWS Coverage on Aerie Pharmaceuticals NEW YORK, NY / ACCESSWIRE / February 10, 2017 / Active Wall St. announces its post-earnings coverage on Eli Lilly and Co. (NYSE: LLY ). The Company reported ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety",2017-02-06 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-huan-113000967.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety, reporting to Kristine Erickson, O.D., Ph.D., Aerie’s Vice President Clinical ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety",2017-02-06 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-huan-113000967.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety, reporting to Kristine Erickson, O.D., Ph.D., Aerie’s Vice President Clinical ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland,2017-02-03 21:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-barry-213000020.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Barry Ivin as Site Director of Aerie’s new manufacturing plant in Athlone, Ireland."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland,2017-02-03 21:30:00 +0000,http://uk.finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-barry-213000094.html,Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland
AERI,AERI:US,BBG001KJ7WJ5,Dearth of Momentum Helps Build 'Wall of Worry',2017-01-27 17:03:00 +0000,http://realmoney.thestreet.com/articles/01/27/2017/dearth-momentum-helps-build-wall-worry?puc=yahoo&cm_ven=YAHOO,Dearth of Momentum Helps Build 'Wall of Worry'
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research",2017-01-23 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-kristine-113000625.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research, reporting to Theresa Heah, M.D., M.B.A., Aerie’s Vice President of Clinical Research ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces Appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research",2017-01-23 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-kristine-113000625.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Kristine Erickson, O.D., Ph.D., as Vice President Clinical Research, reporting to Theresa Heah, M.D., M.B.A., Aerie’s Vice President of Clinical Research ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2017-01-09 11:38:35 +0000,http://biz.yahoo.com/e/170109/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland,2017-01-09 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-enters-lease-agreement-113000548.html?.tsrc=rss,"Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has entered into a lease agreement with the Industrial Development Agency of Ireland for a new manufacturing plant in Athlone, Ireland."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland,2017-01-09 11:30:00 +0000,http://uk.finance.yahoo.com/news/aerie-pharmaceuticals-enters-lease-agreement-113000534.html,Aerie Pharmaceuticals Enters into Lease Agreement for New Manufacturing Plant in Ireland
AERI,AERI:US,BBG001KJ7WJ5,Ocular (OCUL) Reports Positive Phase III Data on Eye Drug,2017-01-05 16:39:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t_8-mg02eRk/ocular-ocul-reports-positive-phase-iii-data-on-eye-drug-cm729808,Shares of Ocular Therapeutix Inc OCUL were up 3 following the company s announcement of positive results from its third phase III trial on lead pipeline candidate 160 Dextenza 0 4 mg for the treatment of post surgical ocular inflammation and pain Notably Ocular has outperformed
AERI,AERI:US,BBG001KJ7WJ5,Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data,2017-01-04 14:41:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OSvDpXm7kUQ/inotek-itek-down-on-poor-phase-iii-glaucoma-drug-data-cm729232,Shares of Inotek Pharmaceuticals Corporation ITEK plunged 71 3 after the company announced that a phase III trial on lead candidate trabodenoson failed to meet the primary endpoint We note that Inotek has underperformed the Zacks classified Medical Biomed Genetics industry in the
AERI,AERI:US,BBG001KJ7WJ5,Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year,2017-01-03 13:42:00 +0000,https://www.thestreet.com/story/13940108/1/inotek-pharma-glaucoma-drug-suffers-study-setback-at-start-of-new-year.html?puc=yahoo&cm_ven=YAHOO,Inotek Pharma Glaucoma Drug Suffers Study Setback at Start of New Year
AERI,AERI:US,BBG001KJ7WJ5,"Commit To Buy Aerie Pharmaceuticals At $22.50, Earn 19.1% Using Options",2016-12-27 17:58:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QMGQtW6o0K4/commit-to-buy-aerie-pharmaceuticals-at-2250-earn-191-using-options-cm726549,Investors considering a purchase of Aerie Pharmaceuticals Inc Symbol AERI stock but cautious about paying the going market price of 39 10 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Rhopressa Regulatory Application Delayed Again,2016-12-27 16:01:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SKx5Cownu_I/aerie-aeri-rhopressa-regulatory-application-delayed-again-cm726396,Aerie Pharmaceuticals Inc AERI announced that the manufacturing facility for its lead candidate Rhopressa will not be ready for pre approval inspection by the FDA until the end of Feb 2017 We note that Aerie has outperformed the Zacks classified Medical Drugs industry in the last
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Rhopressa Regulatory Application Delayed Again,2016-12-27 14:10:02 +0000,http://finance.yahoo.com/news/aerie-aeri-rhopressa-regulatory-application-141002758.html,Aerie (AERI) Rhopressa Regulatory Application Delayed Again
AERI,AERI:US,BBG001KJ7WJ5,Dow books 7th straight weekly gain in muted preholiday trade,2016-12-23 21:32:46 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=48897034-C8F6-11E6-8F68-B8977F716B7C&siteid=yhoof2,"[at MarketWatch] - U.S. stocks ended a thinly traded session with very slight gains on Friday, as the “Santa rally” that has taken indexes to repeated records stalled in the final trading day before the holidays with few ..."
AERI,AERI:US,BBG001KJ7WJ5,Markets Open Flat Heading Into the Holidays,2016-12-23 17:00:00 +0000,http://finance.yahoo.com/news/markets-open-flat-heading-holidays-170000102.html,Markets Open Flat Heading Into the Holidays
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals' stock set to selloff after FDA inspection delay,2016-12-23 12:09:18 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=1FCB354F-5282-456D-81A1-21C125E4F214&siteid=yhoof2,Aerie Pharmaceuticals' stock set to selloff after FDA inspection delay
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-12-23 11:32:08 +0000,http://biz.yahoo.com/e/161223/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for RhopressaTM (netarsudil ophthalmic solution) 0.02%,2016-12-23 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-provides-timing-nda-113000888.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported that it has been notified by its third party manufacturing vendor that the manufacturing line related to RhopressaTM in their Tampa, Florida facility will not be ready ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-12-19 11:32:05 +0000,http://biz.yahoo.com/e/161219/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Appointment of Judith J. Robertson as Chief Commercial Officer,2016-12-19 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-appointment-judith-113000196.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Judith J."
AERI,AERI:US,BBG001KJ7WJ5,Hedge Funds Aren’t Banking On PennyMac Mortgage Investment Trust (PMT),2016-12-07 18:25:05 +0000,http://www.insidermonkey.com/blog/hedge-funds-arent-banking-on-pennymac-mortgage-investment-trust-pmt-500978/,Hedge Funds Aren’t Banking On PennyMac Mortgage Investment Trust (PMT)
AERI,AERI:US,BBG001KJ7WJ5,Should You Buy Aerie Pharmaceuticals Inc (AERI)?,2016-12-07 13:57:49 +0000,http://www.insidermonkey.com/blog/should-you-buy-aerie-pharmaceuticals-inc-aeri-500651/,Should You Buy Aerie Pharmaceuticals Inc (AERI)?
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-12-07 12:41:48 +0000,http://biz.yahoo.com/e/161207/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,2016-12-07 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-completes-enrollment-mercury-113000177.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company’s second Phase 3 registration trial of Roclatan™ 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure in patients with ..."
AERI,AERI:US,BBG001KJ7WJ5,"Is Endologix, Inc. (ELGX) A Good Stock To Buy Right Now?",2016-12-06 22:53:05 +0000,http://www.insidermonkey.com/blog/is-endologix-inc-elgx-a-good-stock-to-buy-right-now-500117/,"Is Endologix, Inc. (ELGX) A Good Stock To Buy Right Now?"
AERI,AERI:US,BBG001KJ7WJ5,Is DHT Holdings Inc (DHT) About to Sink? Hedge Funds Are Fleeing,2016-12-04 00:50:59 +0000,http://www.insidermonkey.com/blog/is-dht-holdings-inc-dht-about-to-sink-hedge-funds-are-fleeing-497968/,Is DHT Holdings Inc (DHT) About to Sink? Hedge Funds Are Fleeing
AERI,AERI:US,BBG001KJ7WJ5,"Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC",2016-12-01 21:52:32 +0000,http://www.investors.com/news/technology/biotechs-aerie-regeneron-tesaro-could-rocket-or-become-ma-fodder/,"Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Participate in Two Investor Conferences in December,2016-12-01 12:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-participate-two-investor-123000407.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company management will participate in the following conferences in December."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals, Inc. :AERI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016",2016-11-28 19:13:31 +0000,http://www.capitalcube.com/blog/index.php/aerie-pharmaceuticals-inc-aeri-us-earnings-analysis-q3-2016-by-the-numbers-november-28-2016/,"Aerie Pharmaceuticals, Inc. :AERI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016"
AERI,AERI:US,BBG001KJ7WJ5,4 Stocks You Should Watch Because They're Breaking Out Higher,2016-11-16 17:40:00 +0000,https://www.thestreet.com/story/13896469/1/4-stocks-you-should-watch-because-they-re-breaking-out-higher.html?puc=yahoo&cm_ven=YAHOO,4 Stocks You Should Watch Because They're Breaking Out Higher
AERI,AERI:US,BBG001KJ7WJ5,Four Momentum Stocks To Watch,2016-11-16 17:36:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/11/16/four-momentum-stocks-to-watch-2/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Four Momentum Stocks To Watch
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-11-15 12:03:19 +0000,http://biz.yahoo.com/e/161115/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Analyst Has 4 Biotech Stocks to Buy Now as Risk Has Dropped Dramatically,2016-11-08 14:55:40 +0000,http://247wallst.com/healthcare-business/2016/11/08/analyst-has-4-biotech-stocks-to-buy-now-as-risk-has-dropped-dramatically/,Analyst Has 4 Biotech Stocks to Buy Now as Risk Has Dropped Dramatically
AERI,AERI:US,BBG001KJ7WJ5,"Which Four Biotechs Are Derisked, Buyable Ahead of Election Day?",2016-11-07 21:29:22 +0000,http://www.investors.com/news/technology/which-four-biotechs-are-derisked-buyable-ahead-of-election-day/,"Which Four Biotechs Are Derisked, Buyable Ahead of Election Day?"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma Dips On 'Minor' Glaucoma Setback And Q3 Miss,2016-11-03 20:16:33 +0000,http://www.investors.com/news/technology/aerie-pharma-dips-on-minor-glaucoma-setback-following-q3-miss/,Aerie Pharma Dips On 'Minor' Glaucoma Setback And Q3 Miss
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report",2016-11-03 18:40:29 +0000,http://biz.yahoo.com/e/161103/aeri10-q.html,"AERIE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus",2016-11-03 17:09:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ndHu1giosA/aerie-aeri-q3-loss-wider-than-expected-pipeline-in-focus-cm703371,Aerie Pharmaceuticals Inc AERI posted third quarter 2016 loss of 81 cents per share including stock based compensation wider than both the Zacks Consensus Estimate of a loss of 70 cents and the year ago loss of 69 cents FindTheCompany Graphiq Being a development
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus",2016-11-03 15:08:03 +0000,http://finance.yahoo.com/news/aerie-aeri-q3-loss-wider-150803672.html,"Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Participate in Three Investor Conferences in November,2016-11-03 11:30:00 +0000,http://uk.finance.yahoo.com/news/aerie-pharmaceuticals-participate-three-investor-113000982.html,Aerie Pharmaceuticals to Participate in Three Investor Conferences in November
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 3Q loss,2016-11-02 21:13:30 +0000,http://sg.finance.yahoo.com/news/aerie-reports-3q-loss-211330596.html,Aerie reports 3Q loss
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016",2016-11-02 20:10:45 +0000,http://www.publicnow.com/view/ED8CF26FC54282E120E3AC45DDD57443F2D27E44,"[at noodls] - IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), (the 'Company'), announced today that its third quarter 2016 financial results will be released after the market closes on ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-11-02 20:05:36 +0000,http://biz.yahoo.com/e/161102/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update,2016-11-02 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-third-quarter-200100673.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2016, along with a general business update."
AERI,AERI:US,BBG001KJ7WJ5,Q3 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close,2016-11-02 11:07:04 +0000,http://biz.yahoo.com/research/earncal/20161102.html?t=aeri,Q3 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close
AERI,AERI:US,BBG001KJ7WJ5,Cigna (CI) Poised to Beat on Earnings in Q3: Here's Why,2016-11-01 20:18:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8L0wPh54oNs/cigna-ci-poised-to-beat-on-earnings-in-q3-heres-why-cm701819,Health insurer Cigna Corp CI is expected to release third quarter financial results before the market opens on Nov 3 In the last reported quarter the company missed the earnings estimate by 17 15 Let s see how things are shaping up for this announcement Why a Likely
AERI,AERI:US,BBG001KJ7WJ5,Regeneron (REGN) Q3 Earnings: Will the Stock Surprise?,2016-11-01 14:16:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/icvMyO34wCM/regeneron-regn-q3-earnings-will-the-stock-surprise-cm701666,Regeneron Pharmaceuticals Inc REGN is scheduled to release third quarter 2016 results on Nov 4 before the opening bell The company s performance has been mixed so far In the last four reported quarters it has surpassed earnings estimates on two occasions and missed the same twice
AERI,AERI:US,BBG001KJ7WJ5,Horizon (HZNP) Q3 Earnings Preview: Stock to Disappoint?,2016-11-01 14:16:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kE4V6w775a8/horizon-hznp-q3-earnings-preview-stock-to-disappoint-cm701664,Horizon Pharma plc HZNP is scheduled to report third quarter 2016 results on Nov 7 before the opening bell Horizon s performance has been far from encouraging with the company missing earnings estimates thrice and surpassing the same in one out of the four trailing quarters Overall
AERI,AERI:US,BBG001KJ7WJ5,Celldex (CLDX): Will the Stock Surprise in Q3 Earnings?,2016-10-31 14:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D6mVgeIRQho/celldex-cldx-will-the-stock-surprise-in-q3-earnings-cm701001,Celldex Therapeutics Inc CLDX is expected to report third quarter 2016 results on Nov 3 Celldex s performance has been encouraging with a three quarter average positive surprise of 4 85 In the last reported quarter the company recorded a positive surprise of 3 03 Let s see how things
AERI,AERI:US,BBG001KJ7WJ5,Conatus (CNAT) Q3 Earnings: What's in Store for the Stock?,2016-10-31 14:17:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xyvVgaSUhp8/conatus-cnat-q3-earnings-whats-in-store-for-the-stock-cm700972,Conatus Pharmaceuticals Inc CNAT is expected to report third quarter 2016 results on Nov 2 Conatus performance so far has been impressive with the company surpassing expectations on three occasions while posting in line results in one Overall the company has posted an average beat
AERI,AERI:US,BBG001KJ7WJ5,Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?,2016-10-31 14:16:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ny3mYZ728cM/exelixis-exel-q3-earnings-whats-in-store-for-the-stock-cm700963,Exelixis Inc EXEL is scheduled to report third quarter 2016 results on Nov 3 after the market closes Exelixis had a mixed track record over the last four quarters The company surpassed expectations twice in the four trailing quarters and missed the same in the remaining two with
AERI,AERI:US,BBG001KJ7WJ5,Ligand (LGND) Q3 Earnings: Is the Stock Likely to Disappoint?,2016-10-28 14:35:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P6XKleSpxLk/ligand-lgnd-q3-earnings-is-the-stock-likely-to-disappoint-cm700217,Ligand Pharmaceuticals Incorporated LGND is scheduled to report third quarter 2016 results on Nov 3 after the market closes Ligand has an impressive track record with its earnings surpassing expectations in three of the trailing four quarters delivering an average positive surprise
AERI,AERI:US,BBG001KJ7WJ5,Endocyte (ECYT): Can the Stock Surprise in Q3 Earnings?,2016-10-28 14:33:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j55Kib51j-E/endocyte-ecyt-can-the-stock-surprise-in-q3-earnings-cm700179,Endocyte Inc ECYT is expected to report third quarter 2016 results on Nov 1 The company has an impressive track record having beaten estimates on three of the trailing four quarters and missing the same once Overall the company has recorded an average positive surprise of 7 44 In
AERI,AERI:US,BBG001KJ7WJ5,"CEMP Plunges, ALDR Promises Data In 1H 2017, AERI Withdraws NDA, AZN, CYH Abuzz",2016-10-28 03:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U_Tgg0vOzIQ/cemp-plunges-aldr-promises-data-in-1h-2017-aeri-withdraws-nda-azn-cyh-abuzz-20161028-00086,"CEMP Plunges, ALDR Promises Data In 1H 2017, AERI Withdraws NDA, AZN, CYH Abuzz"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals (AERI) Q3 Earnings: Will It Beat?,2016-10-28 00:41:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XuyYRKP2Mog/aerie-pharmaceuticals-aeri-q3-earnings-will-it-beat-cm699913,We expect Aerie Pharmaceuticals Inc AERI to beat expectations when it reports third quarter earnings results on Nov 2 after market close However Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected loss thrice in the four
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals (AERI) Q3 Earnings: Will It Beat?,2016-10-27 22:35:10 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-aeri-q3-earnings-223510424.html,Aerie Pharmaceuticals (AERI) Q3 Earnings: Will It Beat?
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-10-27 20:03:01 +0000,http://biz.yahoo.com/e/161027/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of RhopressaTM (netarsudil ophthalmic solution) 0.02%,2016-10-27 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-topline-200100516.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported the successful 90-day topline efficacy results of its Rocket 4 Phase 3 clinical trial of product candidate RhopressaTM, a novel once-daily eye drop being tested for its ..."
AERI,AERI:US,BBG001KJ7WJ5,Pfizer (PFE) to Post Q3 Earnings: How Will the Stock React?,2016-10-27 17:43:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bA9cu08wUk4/pfizer-pfe-to-post-q3-earnings-how-will-the-stock-react-cm699576,Pfizer Inc PFE will be reporting third quarter 2016 earnings on Nov 1 before market open Last quarter the company delivered a positive earnings surprise of 3 23 The pharma giant has been consistently beating earnings expectations The company s earnings surpassed expectations in each
AERI,AERI:US,BBG001KJ7WJ5,Zoetis (ZTS) Q3 Earnings: Stock Likely to Beat Estimates,2016-10-27 12:43:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nx4qPuISsNk/zoetis-zts-q3-earnings-stock-likely-to-beat-estimates-cm699155,Zoetis Inc ZTS is scheduled to report third quarter 2016 results on Nov 2 before the market opens The company has consistently beaten earnings expectations In fact Zoetis earnings surpassed expectations in each of the last four quarters with an average positive surprise of 15 92 In
AERI,AERI:US,BBG001KJ7WJ5,Can Prothena (PRTA) Pull a Surprise This Earnings Season?,2016-10-26 14:53:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VI5LNRq9BeA/can-prothena-prta-pull-a-surprise-this-earnings-season-cm698575,Prothena Corporation plc PRTA is scheduled to report third quarter 2016 results on Nov 1 after the market closes Last reported quarter the company recorded a negative earnings surprise of 32 58 Let s see how things are shaping up for this announcement Factors at
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016",2016-10-25 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announce-third-quarter-113000491.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , , announced today that its third quarter 2016 financial results will be released after the market closes on Wednesday, November 2, 2016."
AERI,AERI:US,BBG001KJ7WJ5,"[$$] Aerie Stock Hits High, Holder Sells $2 Million",2016-10-14 10:04:00 +0000,http://www.barrons.com/articles/aerie-stock-hits-record-high-holder-sells-2-million-1476439448?mod=yahoobarrons&ru=yahoo,"[$$] Aerie Stock Hits High, Holder Sells $2 Million"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Host Investor Day on October 5, 2016",2016-10-09 03:03:39 +0000,http://www.publicnow.com/view/A32AC6A6E1002B7875BA146A66B2202D63058CB3,"[at noodls] - Webcast to Begin at 12:00p.m. Eastern Time IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast of its Investor Day taking ..."
AERI,AERI:US,BBG001KJ7WJ5,Clearing Up Misconceptions Surrounding Aerie Pharmaceuticals,2016-10-06 19:46:18 +0000,http://finance.yahoo.com/news/clearing-misconceptions-surrounding-aerie-pharmaceuticals-194618230.html,Clearing Up Misconceptions Surrounding Aerie Pharmaceuticals
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-10-05 15:02:27 +0000,http://biz.yahoo.com/e/161005/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,6 Best Performing Drug Stocks of September,2016-10-03 14:47:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5jt2X9_U-eY/6-best-performing-drug-stocks-of-september-cm687686,Pharma and biotech stocks have been under a lot of pressure over the last few quarters with the NYSE ARCA Pharmaceutical Index and the NASDAQ Biotechnology index declining 4 1 and 11 7 respectively so far in 2016 Factors like the drug pricing controversy and a changing competitive
AERI,AERI:US,BBG001KJ7WJ5,6 Best Performing Drug Stocks of September,2016-10-03 12:39:12 +0000,http://finance.yahoo.com/news/6-best-performing-drug-stocks-123912721.html,6 Best Performing Drug Stocks of September
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Could Still Be a Bargain After Its Run-Up,2016-09-29 19:21:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ckk7o2Ck3tE/aerie-pharmaceuticals-could-still-be-a-bargain-after-its-run-up-cm686730,Image source Getty Images Aerie Pharmaceuticals NASDAQ AERI 160 reported late stage study data earlier this month suggesting that its Roclatan could reshape the multi billion dollar market for glaucoma treatment The news has already sent Aerie Pharmaceuticals shares
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Could Still Be a Bargain After Its Run-Up,2016-09-29 17:41:05 +0000,http://www.fool.com/investing/general/2016/09/29/aerie-pharmaceuticals-could-still-be-a-bargain-aft.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Aerie Pharmaceuticals Could Still Be a Bargain After Its Run-Up
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-28 11:37:02 +0000,http://biz.yahoo.com/e/160928/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Host Investor Day on October 5, 2016",2016-09-28 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-host-investor-day-113000416.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-22 10:02:43 +0000,http://biz.yahoo.com/e/160922/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex",2016-09-21 20:53:23 +0000,http://biz.yahoo.com/e/160921/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex"
AERI,AERI:US,BBG001KJ7WJ5,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions,2016-09-21 16:23:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JDiIhkH5gYk/3-clinical-stage-biotechs-to-buy-ahead-of-fda-decisions-cm682680,Image source Getty Images Roughly 90 of drugs in clinical trials never make it to the Food and Drug Administration for review so it s not surprising that a green light can be a market moving event especially when it s granted to drugs targeting billion dollar blockbuster
AERI,AERI:US,BBG001KJ7WJ5,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions,2016-09-21 15:01:23 +0000,http://www.fool.com/investing/2016/09/21/3-clinical-stage-biotechs-to-buy-ahead-of-fda-deci.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Clinical-Stage Biotechs to Buy Ahead of FDA Decisions
AERI,AERI:US,BBG001KJ7WJ5,Cloudy Outlook for Aerie Pharma's Glaucoma Drug,2016-09-21 10:30:00 +0000,https://www.thestreet.com/story/13746070/1/cloudy-outlook-for-aerie-pharma-s-glaucoma-drug.html?puc=yahoo&cm_ven=YAHOO,Cloudy Outlook for Aerie Pharma's Glaucoma Drug
AERI,AERI:US,BBG001KJ7WJ5,What's Behind Aerie Pharmaceuticals' 12.9% Rally Today,2016-09-20 18:22:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pAC51IZc9cE/whats-behind-aerie-pharmaceuticals-129-rally-today-cm682182,Image source Getty Images What happened After reporting positive phase 3 trial results for its glaucoma drug Roclatan last week optimism at Wall Street research firms is helping to propel shares in Aerie Pharmaceuticals NASDAQ AERI 160 12 9 higher today at 12 30 p m
AERI,AERI:US,BBG001KJ7WJ5,What's Behind Aerie Pharmaceuticals' 12.9% Rally Today,2016-09-20 16:27:53 +0000,http://www.fool.com/investing/general/2016/09/20/whats-behind-aerie-pharmaceuticals-12-rally-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What's Behind Aerie Pharmaceuticals' 12.9% Rally Today
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Inc. (AERI) Has Climbed To A New High For The Year,2016-09-20 10:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2xbN1To_yi8/aerie-pharmaceuticals-inc-aeri-has-climbed-to-a-new-high-for-the-year-20160920-00225,Aerie Pharmaceuticals Inc. (AERI) Has Climbed To A New High For The Year
AERI,AERI:US,BBG001KJ7WJ5,How to Make Better Trading Decisions,2016-09-19 14:36:37 +0000,http://finance.yahoo.com/tumblr/blog-how-to-make-better-trading-decisions-143642283.html,How to Make Better Trading Decisions
AERI,AERI:US,BBG001KJ7WJ5,Do You Have These Biotech Stocks In Your Portfolio?,2016-09-19 14:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_61YoYvqeDo/do-you-have-these-biotech-stocks-in-your-portfolio-20160919-00807,Do You Have These Biotech Stocks In Your Portfolio?
AERI,AERI:US,BBG001KJ7WJ5,Why Aerie Pharmaceuticals Shares Are Rallying Another 11.9% Today,2016-09-16 21:17:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DOPlp_tEeCY/why-aerie-pharmaceuticals-shares-are-rallying-another-119-today-cm680761,Image source Getty Images What happened After reporting positive phase 3 trial results for its glaucoma drug Roclatan and upping the size of a planned equity offering to 75 million shares in Aerie Pharmaceuticals NASDAQ AERI 160 are climbing 11 9 at 3 30 p m EDT
AERI,AERI:US,BBG001KJ7WJ5,Why Aerie Pharmaceuticals Shares Are Rallying Another 11.9% Today,2016-09-16 19:56:39 +0000,http://www.fool.com/investing/general/2016/09/16/why-aerie-pharmaceuticals-shares-are-rallying-anot.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Aerie Pharmaceuticals Shares Are Rallying Another 11.9% Today
AERI,AERI:US,BBG001KJ7WJ5,"Company News for September 16, 2016",2016-09-16 16:20:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/952L-pHaZz4/company-news-for-september-16-2016-cm680573,160 160 160 Shares of Goodyear Tire amp Rubber Co GT rose 5 1 after the company increased its quarterly dividend by 43 160 160 160 Shares of Aerie Pharmaceuticals Inc AERI surged 44 9 after its treatment for lowering fluid pressure inside the eyeball
AERI,AERI:US,BBG001KJ7WJ5,A Closer Look at Five Stocks Gaining Ground on Friday,2016-09-16 16:02:39 +0000,http://www.insidermonkey.com/blog/a-closer-look-at-five-stocks-gaining-ground-on-friday-475072/,A Closer Look at Five Stocks Gaining Ground on Friday
AERI,AERI:US,BBG001KJ7WJ5,40 Trading Lessons from The PlayBook,2016-09-16 15:25:15 +0000,http://finance.yahoo.com/tumblr/blog-40-trading-lessons-from-the-playbook-152520525.html,40 Trading Lessons from The PlayBook
AERI,AERI:US,BBG001KJ7WJ5,"Company News for September 16, 2016",2016-09-16 14:10:02 +0000,http://finance.yahoo.com/news/company-news-september-16-2016-141002356.html,"Company News for September 16, 2016"
AERI,AERI:US,BBG001KJ7WJ5,Blog Coverage Aerie Pharma Glaucoma Drug Roclatan Surpasses Primary Goals at End Phase III Trials,2016-09-16 13:19:25 +0000,http://news.investornetwork.com/2016/09/16/blog-coverage-aerie-pharma-glaucoma-drug-roclatan-surpasses-primary-goals-at-end-phase-iii-trials/?1=1&1474031965,Blog Coverage Aerie Pharma Glaucoma Drug Roclatan Surpasses Primary Goals at End Phase III Trials
AERI,AERI:US,BBG001KJ7WJ5,"Blog Coverage Aerie Pharma Glaucoma Drug ""Roclatan"" Surpasses Primary Goals at End Phase III Trials",2016-09-16 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-aerie-pharma-glaucoma-131500605.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / September 16, 2016 / Active Wall St. blog coverage looks at the headline from Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) as the company announced on September 14, 2016, that ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-16 10:37:46 +0000,http://biz.yahoo.com/e/160916/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Raises $125 Million in Public Offerings,2016-09-16 10:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-raises-125-million-103000663.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the pricing of a registered underwritten public offering of $75 million of shares of its common stock at a price to the public of $29.50 per share, before deducting underwriting ..."
AERI,AERI:US,BBG001KJ7WJ5,"ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX",2016-09-16 02:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-b5Ef8NgOE/arlz-gets-fda-nod-acrx-scores-hat-trick-otic-on-watch-no-relief-for-nvax-20160916-00036,"ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX"
AERI,AERI:US,BBG001KJ7WJ5,What Happened in the Stock Market Today,2016-09-16 01:17:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kroUZzSIaeE/what-happened-in-the-stock-market-today-cm680312,Image source Getty Images Stocks logged significant gains on Thursday as major indexes climbed throughout the day to end near session highs Investors pushed both the Dow Jones Industrial Average DJINDICES DJI and the S amp P 500 SNPINDEX GSPC indexes up by 1
AERI,AERI:US,BBG001KJ7WJ5,What Happened in the Stock Market Today,2016-09-15 23:16:00 +0000,http://www.fool.com/investing/2016/09/15/what-happened-in-the-stock-market-today.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,What Happened in the Stock Market Today
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma announces secondary offering after big stock jump,2016-09-15 21:17:51 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=76B60A2C-0EF1-4756-8AFE-016130D87C28&siteid=yhoof2,Aerie Pharma announces secondary offering after big stock jump
AERI,AERI:US,BBG001KJ7WJ5,Close Update: Stocks Rally as Economic Data Cools Rate Hike Jitters,2016-09-15 20:57:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JCjXmogRzC4/close-update-stocks-rally-as-economic-data-cools-rate-hike-jitters-cm680258,Stocks rallied on Thursday when an unexpected drop in retail sales and anemic inflation data dimmed the likelihood for the Fed to hike rates next week Stocks rallied on Thursday when an unexpected drop in retail sales and anemic inflation data dimmed the likelihood for the Fed to hike rates
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Skyrockets On Eye Drug News,2016-09-15 20:42:19 +0000,http://www.investors.com/news/technology/aerie-pharmaceuticals-skyrockets-on-eye-drug-news/,Aerie Pharmaceuticals Skyrockets On Eye Drug News
AERI,AERI:US,BBG001KJ7WJ5,"Health Care Sector Update for 09/15/2016: XNCR,AERI,GBSN",2016-09-15 20:37:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FrtwNHVoDlc/health-care-sector-update-for-09152016-xncraerigbsn-cm680237,Top Health Care StocksTop Health Care Stocks JNJ 0 78 JNJ 0 78 PFE 0 79 PFE 0 79 MRK 0 92 MRK 0 92 ABT 1 86 ABT 1 86 AMGN 1 68 AMGN 1 68 Health care stocks were surging today with the NYSE Health Care Index holding on to a 1 0 gain while shares of health care companies in
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-15 20:17:51 +0000,http://biz.yahoo.com/e/160915/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Announces Public Offering of Common Stock,2016-09-15 20:05:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-announces-public-offering-200500401.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock."
AERI,AERI:US,BBG001KJ7WJ5,"Trending Tickers: AAPL, TMUS, FIT, AERI",2016-09-15 19:01:00 +0000,http://realmoney.thestreet.com/articles/09/15/2016/trending-tickers-aapl-tmus-fit-aeri?puc=yahoo&cm_ven=YAHOO,"Trending Tickers: AAPL, TMUS, FIT, AERI"
AERI,AERI:US,BBG001KJ7WJ5,Why Aerie Pharmaceuticals Is Soaring 54% Today,2016-09-15 17:42:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mWBsQXY-Lw4/why-aerie-pharmaceuticals-is-soaring-54-today-cm680146,Image source Steve Jurvetson via Flickr What happened After reporting positive phase 3 trial results for its glaucoma drug Roclatan shares in Aerie Pharmaceuticals NASDAQ AERI 160 skyrocketed 54 at 12 30 p m EST So what The market for lowering intraocular
AERI,AERI:US,BBG001KJ7WJ5,"Health Care Sector Update for 09/15/2016: LAKE,AERI,GBSN",2016-09-15 17:42:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/grpj35HjASY/health-care-sector-update-for-09152016-lakeaerigbsn-cm680172,Top Health Care StocksTop Health Care Stocks JNJ 0 32 JNJ 0 32 PFE 0 32 PFE 0 32 MRK 0 47 MRK 0 47 ABT 1 37 ABT 1 37 AMGN 1 28 AMGN 1 28 Health care stocks were climbing today with the NYSE Health Care Index holding on to a 0 6 gain while shares of health care companies in
AERI,AERI:US,BBG001KJ7WJ5,"Midday Update: Stocks Buoyed by Anemic Retail Sales, Support For S&P 500 at 2,120",2016-09-15 17:42:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lqccW_01tMo/midday-update-stocks-buoyed-by-anemic-retail-sales-support-for-sp-500-at-2120-cm680171,Stocks were higher in Thursday s midday trade as underwhelming economic data on consumer spending and wholesale prices dims the likelihood for the Federal Reserve to hike rates next week Coupled with strong support for the S amp P 500 at 2 120 and solid gains in oil futures the benchmark
AERI,AERI:US,BBG001KJ7WJ5,Why Aerie Pharmaceuticals Is Soaring 54% Today,2016-09-15 17:07:58 +0000,http://www.fool.com/investing/general/2016/09/15/why-aerie-pharmaceuticals-is-soaring-54-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Aerie Pharmaceuticals Is Soaring 54% Today
AERI,AERI:US,BBG001KJ7WJ5,Cantor Lifts Aerie's Price Target To $50 Following 'Rock Solid Phase 3 Roclatan Results',2016-09-15 16:11:48 +0000,http://finance.yahoo.com/news/cantor-lifts-aeries-price-target-161148011.html,Cantor Lifts Aerie's Price Target To $50 Following 'Rock Solid Phase 3 Roclatan Results'
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan,2016-09-15 15:20:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PJgwXxyEzYY/aerie-aeri-stock-up-on-positive-phase-iii-data-on-roclatan-cm679959,Aerie Pharmaceuticals Inc s AERI shares gained 7 5 after the company announced successful 90 day primary efficacy data from the first phase III registration study Mercury 1 on Roclatan Roclatan is a fixed dose combination of Aerie s lead candidate Rhopressa netarsudil
AERI,AERI:US,BBG001KJ7WJ5,"3 Stocks to Watch Thursday: Viacom, Inc. (VIAB), Aerie Pharmaceuticals Inc (AERI) and Bluebird Bio Inc (BLUE)",2016-09-15 15:19:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AcPONEzys2A/3-stocks-to-watch-thursday-viacom-inc-viab-aerie-pharmaceuticals-inc-aeri-and-bluebird-bio-inc-blue-cm679968,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Tech stocks rose 0 6 yesterday which was a bright spot among what was otherwise a dreary day for U S equities The S amp P 500 fell 0 1 the Dow Jones Industrial Average lost 0
AERI,AERI:US,BBG001KJ7WJ5,Why Shares of Aerie Pharmaceuticals (AERI) are Soaring Today,2016-09-15 14:23:00 +0000,https://www.thestreet.com/story/13741472/1/why-shares-of-aerie-pharmaceuticals-aeri-are-soaring-today.html?puc=yahoo&cm_ven=YAHOO,Why Shares of Aerie Pharmaceuticals (AERI) are Soaring Today
AERI,AERI:US,BBG001KJ7WJ5,Stock Futures Trim Gains as Econ Data Fails to Extinguish Rate Hike Jitters,2016-09-15 13:55:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7pQUZHaSFrs/stock-futures-trim-gains-as-econ-data-fails-to-extinguish-rate-hike-jitters-cm679911,Stock futures are trimming some of their early gains as this morning s flood of economic data was not seen as compelling enough to pull the plug on possible rate hike next week Stock futures are trimming some of their early gains as this morning s flood of economic data was not seen as
AERI,AERI:US,BBG001KJ7WJ5,"Pre-Market Most Active for Sep 15, 2016 :  AEG, AAPL, AZN, AERI, XIV, QQQ, ACRX, TTM, BAC, TVIX, NOK, CS",2016-09-15 13:04:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u86sR3w3Ttk/pre-market-most-active-for-sep-15-2016-aeg-aapl-azn-aeri-xiv-qqq-acrx-ttm-bac-tvix-nok-cs-cm679833,The NASDAQ 100 Pre Market Indicator is up 13 4 to 4 759 46 The total Pre Market volume is currently 3 960 803 shares traded The following are the most active stocks for the pre market session Aegon NV AEG is 0 01 at 3 82 with 1 097 400 shares traded AEG s
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan,2016-09-15 13:04:01 +0000,http://finance.yahoo.com/news/aerie-aeri-stock-positive-phase-130401792.html,Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan
AERI,AERI:US,BBG001KJ7WJ5,"Apogee, Apigee and Everything In-Between: The Latest On These 5 Trending Stocks",2016-09-15 11:59:10 +0000,http://www.insidermonkey.com/blog/apogee-apigee-and-everything-in-between-the-latest-on-these-5-trending-stocks-474702/,"Apogee, Apigee and Everything In-Between: The Latest On These 5 Trending Stocks"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Inc. (AERI) Has Surged To A New High On Study Results,2016-09-15 09:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1KB0ilzyqMc/aerie-pharmaceuticals-inc-aeri-has-surged-to-a-new-high-on-study-results-20160915-00599,Aerie Pharmaceuticals Inc. (AERI) Has Surged To A New High On Study Results
AERI,AERI:US,BBG001KJ7WJ5,U.S. stock futures stuck in tight ranges ahead of data deluge,2016-09-15 09:12:29 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=6CBB0556-7B14-11E6-B9F7-409A1DD77891&siteid=yhoof2,U.S. stock futures stuck in tight ranges ahead of data deluge
AERI,AERI:US,BBG001KJ7WJ5,"Data Boosts AERI, FDA Panel Snubs SPPI, D-Day For ACRX Today, VTAE Abuzz",2016-09-15 02:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TKeSj7mxQ1A/data-boosts-aeri-fda-panel-snubs-sppi-dday-for-acrx-today-vtae-abuzz-20160915-00082,"Data Boosts AERI, FDA Panel Snubs SPPI, D-Day For ACRX Today, VTAE Abuzz"
AERI,AERI:US,BBG001KJ7WJ5,"After Hours Most Active for Sep 14, 2016 :  PG, HBAN, GE, T, CSCO, AKS, DNR, MDLZ, MSFT, AERI, NE, YHOO",2016-09-14 23:24:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jnJ1It1giBc/after-hours-most-active-for-sep-14-2016-pg-hban-ge-t-csco-aks-dnr-mdlz-msft-aeri-ne-yhoo-cm679606,The NASDAQ 100 After Hours Indicator is down 3 38 to 4 742 68 The total After hours volume is currently 36 541 089 shares traded The following are the most active stocks for the after hours session Procter amp Gamble Company The PG is unchanged at 87 01
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma shares jump more than 60% on eye-drug study results,2016-09-14 20:22:04 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=70C15B53-2537-4DFA-B2B2-A81FE37EE17A&siteid=yhoof2,Aerie Pharma shares jump more than 60% on eye-drug study results
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-14 20:03:12 +0000,http://biz.yahoo.com/e/160914/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results,2016-09-14 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-positive-roclatan-200100888.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today reported the successful 90-day primary efficacy results of its 12-month Phase 3 “Mercury 1” clinical trial for its fixed-dose combination product candidate, RoclatanTM."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals, Inc. :AERI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016",2016-09-13 19:23:53 +0000,http://www.capitalcube.com/blog/index.php/aerie-pharmaceuticals-inc-aeri-us-earnings-analysis-q2-2016-by-the-numbers-september-13-2016/,"Aerie Pharmaceuticals, Inc. :AERI-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016"
AERI,AERI:US,BBG001KJ7WJ5,4 Biotechs Set to Provide a Shot in the Arm,2016-09-09 14:24:00 +0000,http://realmoney.thestreet.com/articles/09/09/2016/4-biotechs-set-provide-shot-arm?puc=yahoo&cm_ven=YAHOO,4 Biotechs Set to Provide a Shot in the Arm
AERI,AERI:US,BBG001KJ7WJ5,"CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails",2016-09-07 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GVbsP55jeVQ/cerc-data-due-dec-samurai-brings-cheer-to-clcd-tnxp-slumps-as-study-fails-20160907-00032,"CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails"
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-09-06 20:06:15 +0000,http://biz.yahoo.com/e/160906/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa™ (netarsudil ophthalmic solution) 0.02%,2016-09-06 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-submits-drug-application-200100070.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the submission of its New Drug Application to the U.S."
AERI,AERI:US,BBG001KJ7WJ5,"Noteworthy Thursday Option Activity: AERI, IDA, PAY",2016-09-01 21:17:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3baGevSODjI/noteworthy-thursday-option-activity-aeri-ida-pay-cm673733,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Aerie Pharmaceuticals Inc Symbol AERI where a total volume of 2 912 contracts has been traded thus far today a contract volume which is representative of
AERI,AERI:US,BBG001KJ7WJ5,"Notable Wednesday Option Activity: WMT, AERI, OPHT",2016-08-24 16:39:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CP5HAxceYV0/notable-wednesday-option-activity-wmt-aeri-opht-cm669572,"Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Wal Mart Stores, Inc. (Symbol WMT), where a total volume of 48,545 contracts has been traded thus far today, a contract"
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-08-10 10:32:39 +0000,http://biz.yahoo.com/e/160810/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus",2016-08-04 14:58:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Sp0CL-5GvBg/aerie-aeri-q2-loss-wider-than-expected-pipeline-in-focus-cm660286,"Aerie Pharmaceuticals, Inc.AERI posted second quarter 2016 loss of 87 cents per share (including stock based compensation), wider than both the Zacks Consensus Estimate of a loss of 75 cents and the year ago loss of 73 cents. Being"
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report",2016-08-04 14:57:35 +0000,http://biz.yahoo.com/e/160804/aeri10-q.html,"AERIE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus",2016-08-04 13:08:01 +0000,http://finance.yahoo.com/news/aerie-aeri-q2-loss-wider-130801870.html,"Aerie (AERI) Q2 Loss Wider than Expected, Pipeline in Focus"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference,2016-08-04 11:30:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-present-canaccord-genuity-113000761.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016 at 12:30 p.m."
AERI,AERI:US,BBG001KJ7WJ5,"AXGN Making News, Milestone Events Lined Up For NBIX, Cesca Plays It Cool",2016-08-04 00:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AMgKJTxU77c/axgn-making-news-milestone-events-lined-up-for-nbix-cesca-plays-it-cool-20160804-00007,"AXGN Making News, Milestone Events Lined Up For NBIX, Cesca Plays It Cool"
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 2Q loss,2016-08-03 21:13:44 +0000,http://sg.finance.yahoo.com/news/aerie-reports-2q-loss-211344262.html,Aerie reports 2Q loss
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016",2016-08-03 20:22:17 +0000,http://www.publicnow.com/view/30FEC74B05AFA0353FAC90C788BC8EDEFB046D47,"[at noodls] - IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the 'Company'), announced today that its second quarter 2016 financial results will be released after the market closes on ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-08-03 20:13:03 +0000,http://biz.yahoo.com/e/160803/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update,2016-08-03 20:01:00 +0000,http://finance.yahoo.com/news/aerie-pharmaceuticals-reports-second-quarter-200100361.html,"[Business Wire] - Aerie Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2016, along with a general business update."
AERI,AERI:US,BBG001KJ7WJ5,Q2 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close,2016-08-03 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20160803.html?t=aeri,Q2 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close
AERI,AERI:US,BBG001KJ7WJ5,"Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More",2016-08-02 16:59:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qN_lz_ygz44/drug-stocks-to-watch-for-earnings-on-aug-3-zts-exel-more-cm658976,"In the thick of Q2 earnings season, we see a clear trend of continuing earnings decline for the benchmark S&P 500 index the fifth quarter in a row. As for beat ratios, they aren't all that bad. Of the"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie owner buys 250,000 shares",2016-08-02 16:28:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gi93n_SSceM/aerie-owner-buys-250000-shares-cm658994,"James Tananbaum, 10% owner of Aerie Pharmaceuticals Inc  ( AERI ), bought 250,000  shares of the company's common stock on July 22. Tananbaum bought the shares at $17.50 for a total of  $4,375,000.00.     InvestorsKeyhole Trade AlertIK >"
AERI,AERI:US,BBG001KJ7WJ5,"Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More",2016-08-02 14:30:02 +0000,http://finance.yahoo.com/news/drug-stocks-watch-earnings-aug-143002593.html,"Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More"
AERI,AERI:US,BBG001KJ7WJ5,What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?,2016-08-02 00:52:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mE9KUKlHsPI/what-awaits-aerie-pharmaceuticals-aeri-in-q2-earnings-cm658490,"Aerie Pharmaceuticals, Inc.AERI is scheduled to report second quarter 2016 results after the market closes on Aug 3. Aerie's performance over the last four quarters has been disappointing. The company reported a wider than expected loss thrice in the"
AERI,AERI:US,BBG001KJ7WJ5,What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?,2016-08-01 22:38:10 +0000,http://finance.yahoo.com/news/awaits-aerie-pharmaceuticals-aeri-q2-223810883.html,What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
AERI,AERI:US,BBG001KJ7WJ5,"Massive Netflix Purchase Highlights Insider Buying: General Electric, Delta Airlines, Mattress Firm, Bank of New York Mellon and More",2016-07-31 14:15:03 +0000,http://247wallst.com/investing/2016/07/31/massive-netflix-purchase-highlights-insider-buying-general-electric-delta-airlines-mattress-firm-bank-of-new-york-mellon-and-more/,"Massive Netflix Purchase Highlights Insider Buying: General Electric, Delta Airlines, Mattress Firm, Bank of New York Mellon and More"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference,2016-07-06 11:41:08 +0000,http://www.publicnow.com/view/1CD52F31F286DD3C95BFD3AEE187A670CCA213E3,"[at noodls] - July 6, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Other Events",2016-06-22 10:31:31 +0000,http://biz.yahoo.com/e/160622/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Other Events"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma stays on track with late-stage trial enrollment,2016-06-16 14:55:24 +0000,http://www.bizjournals.com/triangle/news/2016/06/16/aerie-aeri-pharma-stays-on-track-with-late.html?ana=yahoo,Aerie Pharma stays on track with late-stage trial enrollment
AERI,AERI:US,BBG001KJ7WJ5,Aerie Completes Enrollment Of Rocket 4 Final Stage Clinical Study Of RhopressaTM 0.02%,2016-06-16 13:55:06 +0000,http://finance.yahoo.com/news/aerie-completes-enrollment-rocket-4-135506313.html,Aerie Completes Enrollment Of Rocket 4 Final Stage Clinical Study Of RhopressaTM 0.02%
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of RhopressaTM (netarsudil ophthalmic solution) 0.02%,2016-06-16 12:39:10 +0000,http://www.publicnow.com/view/8CA9FFA11F1709F35C58EC05DE425F8025B60F28,"[at noodls] - June 16, 2016 - Trial On Track for Topline 90-day Interim Efficacy Readout in Q4 2016 - -Rocket 4 Designed for EU Filing; Not Required for US NDA Filing- IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, ..."
AERI,AERI:US,BBG001KJ7WJ5,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders",2016-06-09 20:32:07 +0000,http://biz.yahoo.com/e/160609/aeri8-k.html,"AERIE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Participate in Two Investor Conferences in June,2016-06-02 11:35:05 +0000,http://www.publicnow.com/view/40B70F755FC4BA3A612B20E2EC0C8A2522EDE366,"[at noodls] - June 2, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ..."
AERI,AERI:US,BBG001KJ7WJ5,"Notable Wednesday Option Activity: BOX, AERI, AIG",2016-05-18 20:56:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EaIkHACxB9w/notable-wednesday-option-activity-box-aeri-aig-cm623041,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Box Inc (Symbol BOX), where a total of 2,668 contracts have traded so far, representing approximately 266,800 underlying shares. That amounts to"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,2016-05-05 10:41:17 +0000,http://www.publicnow.com/view/3473F640226360BF2ADE3612BB3F188A0DD9DED0,"[at noodls] - May 5, 2016 Trial On Track for Topline 90-day Efficacy Readout in Q3 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference,2016-05-04 11:40:07 +0000,http://www.publicnow.com/view/6E29965349AE4A6758464B47B5CDDBC4407D1F2B,"[at noodls] - May 4, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q1 Loss Wider than Expected, Pipeline in Focus",2016-05-03 14:52:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6XchxO4kdDk/aerie-aeri-q1-loss-wider-than-expected-pipeline-in-focus-cm615293,"Aerie Pharmaceuticals, Inc.AERI posted a first quarter 2016 loss of 85 cents per share (including stock based compensation), wider than both the Zacks Consensus Estimate of a loss of 66 cents and the year ago loss of 70 cents."
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 1Q loss,2016-05-02 20:47:36 +0000,http://sg.finance.yahoo.com/news/aerie-reports-1q-loss-204736063.html,Aerie reports 1Q loss
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update,2016-05-02 20:10:05 +0000,http://www.publicnow.com/view/FC72008A3D3F4D6D8FBD0352E9FC00AAFB06B338,"[at noodls] - May 2, 2016 Company on Track to File NDA in 3Q 2016 for Rhopressa™ (netarsudil ophthalmic solution) 0.02% Mercury 1 Phase 3 Topline Readout for Roclatan™(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% ..."
AERI,AERI:US,BBG001KJ7WJ5,"Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA",2016-04-29 15:10:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HggeAW3r10g/drug-stocks-q1-earnings-preview-aegr-aeri-mack-prta-cm613739,"The going has been quite satisfactory as we stand in the thick of the first earnings season of the year. As per our Earnings Trends report , approximately 209 S&P 500 companies (52.4% of the index's total market capitalization) have"
AERI,AERI:US,BBG001KJ7WJ5,Aerie (AERI): Can the Stock Pull a Surprise in Q1 Earnings?,2016-04-28 01:08:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I74yHkMIZro/aerie-aeri-can-the-stock-pull-a-surprise-in-q1-earnings-cm612791,"Aerie Pharmaceuticals, Inc . AERI is scheduled to report first quarter 2016 results after the market closes on May 2. Aerie's performance over the last four quarters has been disappointing. The company reported a wider than expected loss in"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Monday, May 2, 2016",2016-04-25 11:47:11 +0000,http://www.publicnow.com/view/BE6F9472E416CD1E5D55A14611A9881722476B4C,"[at noodls] - April 25, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the 'Company'), announced today that its first quarter 2016 financial results will be released after the market ..."
AERI,AERI:US,BBG001KJ7WJ5,Will Aerie Pharmaceuticals (AERI) Continue to Surge Higher?,2016-04-13 14:07:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iJ3rJzrjS-A/will-aerie-pharmaceuticals-aeri-continue-to-surge-higher-cm605673,"As of late, it has definitely been a great time to be an investor in Aerie Pharmaceuticals, Inc.AERI . The stock has moved higher by 7.7% in the past month, while it is also above its 20 Day SMA"
AERI,AERI:US,BBG001KJ7WJ5,"Thursday's ETF Movers: XPH, XRT",2016-04-07 18:59:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3BUcW3Qrj0s/thursdays-etf-movers-xph-xrt-cm603248,"In trading on Thursday, the SPDR S&P Pharmaceuticals ETF ( XPH ) is outperforming other ETFs, up about 3.5% on the day. Components of that ETF showing particular strength include shares of Relypsa ( RLYP ), up about 56.8%"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference,2016-04-05 11:48:28 +0000,http://www.publicnow.com/view/94DD0A8704698D7129F29060D46C57799DD0E97F,"[at noodls] - April 5, 2016 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan,2016-03-29 22:26:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ujdwxfGN7N4/aerie-starts-dosing-in-registration-trial-mercury-2-on-roclatan-cm599167,"Aerie Pharmaceuticals, Inc . AERI announced that last week, it has initiated dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02% 0.005%. We note that Roclatan is a fixed dose combination of"
AERI,AERI:US,BBG001KJ7WJ5,"Health Care Sector Update for 03/28/2016: AERI,ALDR,APRI",2016-03-28 20:19:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qhrkpg6wLZo/health-care-sector-update-for-03282016-aerialdrapri-cm598540,"Top Health Care Stocks JNJ +0.08% PFE 1.08% MRK +0.39% ABT 0.41% AMGN 0.28% Health care stocks were slightly lower this afternoon, with the NYSE Health Care Index dropping less than 0.1% while shares of health care companies in"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%,2016-03-28 10:48:50 +0000,http://www.publicnow.com/view/2861F26652E79D4A00CF482A013C8258F6C7AE6E,"[at noodls] - March 28, 2016 First Patient Dosed in 90-Day Efficacy Trial Named Mercury 2 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) ('Aerie' or the 'Company'), a clinical-stage pharmaceutical ..."
AERI,AERI:US,BBG001KJ7WJ5,"Health Care Sector Update for 03/03/2016: AERI,CRMD,SSH",2016-03-03 21:35:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0s4lXRJhbWQ/health-care-sector-update-for-03032016-aericrmdssh-cm588075,"Top Health Care Stocks JNJ 0.34% PZE 0.32% MRK 1.22% ABT 0.34% AMGN 1.13% Health care stocks were mostly lower late today, with the NYSE Health Care Index declining about about 0.5% while shares of health care companies in"
AERI,AERI:US,BBG001KJ7WJ5,"Aerie (AERI) Q4 Loss Wider than Expected, Pipeline in Focus",2016-03-02 16:43:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t5YnAofGUDg/aerie-aeri-q4-loss-wider-than-expected-pipeline-in-focus-cm587282,"Aerie Pharmaceuticals, IncAERI posted a fourth quarter 2015 loss of 76 cents per share (including stock based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents and the year ago loss of 69 cents."
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 4Q loss,2016-03-01 21:25:49 +0000,http://sg.finance.yahoo.com/news/aerie-reports-4q-loss-212549354.html,Aerie reports 4Q loss
AERI,AERI:US,BBG001KJ7WJ5,"After-Hours Earnings Report for March 1, 2016 :  ROST, GWRE, VEEV, ASNA, NKTR, DAR, SQM, BOBE, TIVO, CHUY, EPIQ, AERI",2016-03-01 20:58:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tqsbLX2Zodg/after-hours-earnings-report-for-march-1-2016-rost-gwre-veev-asna-nktr-dar-sqm-bobe-tivo-chuy-epiq-aeri-cm586865,"The following companies are expected to report earnings after hours on 03 01 2016. Visit our Earnings Calendar for a full list of expected earnings releases.  Ross Stores, Inc. ( ROST ) is reporting for the"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals to Participate in Several Conferences in November,2015-11-05 12:50:13 +0000,http://www.noodls.com/view/D3F55B0B4470901642772437C47D651FBBEAF174,"[at noodls] - November 5, 2015 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Host Investor and Media Briefing During the 2015 American Academy of Ophthalmology Annual Meeting on November 13, 2015",2015-11-04 12:57:09 +0000,http://www.noodls.com/view/2B47E12F198182764CB2F46E4B19C4B6BD332E62,"[at noodls] - November 4, 2015 -Webcast to Begin at 12:00p.m. Pacific Time- IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast in conjunction ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie reports 3Q loss,2015-11-03 21:38:06 +0000,http://sg.finance.yahoo.com/news/aerie-reports-3q-loss-213806202.html,Aerie reports 3Q loss
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Business Update,2015-11-03 21:27:12 +0000,http://www.noodls.com/view/07E9632D9F5869C524C567F352BD80FAF08EE99C,"[at noodls] - November 3, 2015 - Based on FDA Meetings, Company Expects to File Rhopressa TM NDA in 3Q 2016 - Conference Call and Webcast Today, November 3, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, ..."
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Tuesday, November 3, 2015",2015-10-20 12:02:13 +0000,http://www.noodls.com/view/70FA6B54D8FE1B843B024EA8B375334BB172EFE5,"[at noodls] - Aerie Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Tuesday, November 3, 2015"
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of RhopressaTM,2015-09-24 10:48:15 +0000,http://www.noodls.com/view/AF434F2C433B39A74813DAE6D825975CBB82BB8B,"[at noodls] - First Patient Dosed in 90-Day Efficacy Trial Named Rocket 4 IRVINE , Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of RoclatanTM,2015-09-21 11:05:12 +0000,http://www.noodls.com/view/7A91D557C8386065F3D2A30AB192E49A8913A76A,"[at noodls] - First Patient Dosed in 90-Day Efficacy and 12 Month Safety Trial Named Mercury 1 IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals' eye drop succeeds in late-stage study,2015-09-17 01:27:51 +0000,http://sg.finance.yahoo.com/news/aerie-pharmaceuticals-eye-drop-succeeds-012751053.html,Aerie Pharmaceuticals' eye drop succeeds in late-stage study
AERI,AERI:US,BBG001KJ7WJ5,"Aerie Pharmaceuticals Announces that Richard A. Lewis, M.D., Has Joined as Chief Medical Officer",2015-09-16 20:09:09 +0000,http://www.noodls.com/view/CE119D04FF671A66129FDDF4A7B9E5C48A46F27A,"[at noodls] - Company Also Adds Key Leadership Talent to Clinical Researchand Medical Affairs Group IRVINE , Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results,2015-09-16 20:09:09 +0000,http://www.noodls.com/view/8C391EE29053585CC2F2141EF3219F6CF270295E,"[at noodls] - Rhopressa™ Achieves Primary Clinical Endpoint in Rocket 2 Study Conference Call and Webcast Today, September 16, at 5:00 p.m. ET IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration,2015-09-08 20:18:02 +0000,http://www.noodls.com/view/79422F1C29B028A146F4F43B938B0DAA88A57297,"[at noodls] - -Focused on Anti-Beta Amyloid Small Molecule Product Candidate for Neuroprotection and Dry AMD- IRVINE, Calif. & TEL AVIV, Israel--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage ..."
AERI,AERI:US,BBG001KJ7WJ5,Aerie Pharma plunges aftermarket as Rhopressa study fails,2015-04-23 22:42:34 +0000,http://sg.finance.yahoo.com/news/aerie-pharma-plunges-aftermarket-rhopressa-224234082.html,Aerie Pharma plunges aftermarket as Rhopressa study fails
AERI,AERI:US,BBG001KJ7WJ5,New wave of drugs poised to shake up glaucoma treatment,2015-02-10 12:00:00 +0000,http://uk.finance.yahoo.com/news/wave-drugs-poised-shake-glaucoma-120000703.html,New wave of drugs poised to shake up glaucoma treatment
AERI,AERI:US,BBG001KJ7WJ5,Aerie posts 3Q loss,2014-11-11 21:27:58 +0000,http://sg.finance.yahoo.com/news/aerie-posts-3q-loss-212758868--finance.html,Aerie posts 3Q loss
AERI,AERI:US,BBG001KJ7WJ5,"BUZZ-U.S. Stocks on the Move-CBS, Energy stocks, Medical Action",2014-06-25 17:19:15 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-cbs-153039681.html,"BUZZ-U.S. Stocks on the Move-CBS, Energy stocks, Medical Action"
AERI,AERI:US,BBG001KJ7WJ5,"BUZZ-U.S. Stocks on the Move-Heron, Valero, Valmont, Medical Action",2014-06-25 14:10:49 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-heron-141049705.html,"BUZZ-U.S. Stocks on the Move-Heron, Valero, Valmont, Medical Action"
